 	 	 	N (%)

Age, years	Median	63.0

Range	33–81

Sex	Male		31 (70.5%)

Female		13 (29.5%)

ECOG performance status	0		24 (54.5%)

1		15 (34.1%)

2		5 (11.4%)

Primary site	Colon		22 (50.0%)

Rectum		20 (45.5%)

Colorectal		2 (4.5%)

Metastatic sites	Liver		31 (70.5%)

Lung		18 (40.9%)

Lymph nodes		8 (18.2%)

Other (mediastinum, pelvis, perineum)		4 (9.1%)

Peritoneum		2 (4.5%)

Number of target lesions	1		11 (25.0%)

2		12 (27.3%)

3		10 (22.7%)

4 or more		11 (25.0%)

Prior therapy	Surgery		38 (86.4%)

Radiotherapy		11 (25.0%)

Chemotherapy

 Metastatic		44 (100.0%)

Time from initial diagnosis to inclusion, months	Median	17.0

Range	2.8–81.1

			N (%)

Age, years	Median	63.0

Range	33–81

S	Male		31 (70.5%)

F		1

			N (%)

ex	emale		3 (29.5%)

ECOG performance status	0		24 (54.5%)

1		15 (34.1%)

2		5 (11.4%)

Primary site	Colon		22 (50.0%)

Rectum		20 (45.5%)

Colorectal		2 (4.5%)

Metastatic sites	Liver		31 (70.5%)

Lung		18 (40.9%)

Lymph nodes		8 (18.2%)

Other (mediastinum, pelvis, perineum)		4 (9.1%)

Peritoneum		2 (4.5%)

Number of target lesions	1		11 (25.0%)

2		12 (27.3%)

3		10 (22.7%)

4 or more		11 (25.0%)

Prior therapy	Surgery		38 (86.4%)

Radiotherapy		11 (25.0%)

Chemotherapy

Metastatic		44 (100.0%)

Time from initial diagnosis to inclusion, months	Median	17.0

Range	2.8–81.1


Category of intervention	Effective interventions for nurse retention	Strength of evidence*

A. Education and continuous professional development interventions	-Recruitment from, and training in, rural areas	Moderate [26]#

-Targeted admission of students from rural background	Moderate [28]#

-Early and increased exposure to rural practice during undergraduate studies

-Support for continuous professional development

B. Regulatory interventions	-Increased opportunities for recruitment to civil service	Low [25]#

-Recognizing overseas qualifications

-Producing different types of health workers

C. Financial incentives	-Direct and indirect financial incentives (direct payments, service-requiring scholarships, educational loans with service requirements, loan repayment programs)	Moderate [24]#

Low [25]

D. Personal and professional support	-General improvement in rural infrastructure (housing, roads, phones, water supplies, radio communication, etc.)	Strong [25]

-Supportive supervision (mentorship, preceptorship, clinical supervision)	Moderate [26]#

 	-Measures to reduce health workers’ feeling of isolation (professional/specialist networks, telemedicine and telehealth)	Moderate [27]#


Brain region	MR image	PET image

Volume(mm3)	Mean voxel Activity concentrationa (kBq·mL−1)	Mean ROI activity(Bq)	Volume(mm3)	Mean voxelActivity concentrationb (kBq·mL−1)	Mean ROIactivity(Bq)

Left striatum	16.4	0.50	8.19	15.3	0.52	7.95

Right striatum	15.1	0.50	7.56	14.7	0.50	7.30

Hippocampus	26.4	0.50	13.22	26.8	0.50	13.38

Frontal cortex 	46.1	0.50	23.03	48.6	0.50	24.13

Posterior cortex 	49.6	0.50	24.80	48.9	0.49	23.96

Medulla oblongata	15.7	0.50	7.85	15.8	0.49	7.75

Cerebellum	86.7	0.50	43.35	86.0	0.49	42.14

Brain region	MR image

Volume(mm3)

Left striatum	16.4

Right striatum	15.1

Hippocampus	26.4

Frontal cortex	46.1

Posterior cortex	49.6

Medulla oblongata	15.7

Cerebellum	86.7


Reaction type	All reactions	Reaction following GAb

 	N	% of all reactionsa	N	% of reaction types, where reaction followed GA

Nausea and/or vomiting	400	27.5%	295	73.8%

Pruritus	243	16.7%	232	95.5%

Constipation	155	10.6%	107	69.0%

Diarrhea (9/88 with vomiting)	88	6.0%	0	0.0%

Somnolence (without cardio-respiratory symptoms)	50	3.4%	34	68.0%

Respiratory depression (41)/arrest (3)	44	3.0%	43	97.7%

Candidiasis	41	2.8%	0	0.0%

Urinary retention	40	2.7%	37	92.5%

Rash	31	2.1%	3	9.7%

Hypokalemia	25	1.7%	0	0.0%

Hypotension	22	1.5%	9	40.9%

Hepatotoxicity(6)/increased transaminases (12)c	18	1.2%	1	5.6%

Stomatitis	16	1.1%	0	0.0%

Myoclonus	15	1.0%	14	93.3%

Pancytopenia	13	<1%	0	0.0%

Hyperglycemia	12	<1%	0	0.0%

Hypertension	11	<1%	2	18.2%

Allergic reactions	10	<1%	3	30.0%

Pain (4/10 pain in jaw, 2/10 back pain)	10	<1%	0	0.0%

Other reactions ( occurred <10 times)	213	14.6%	65	30.5%

Total	1,457	 	845	58.0%


Number of patients	Disease progression	Localized	P Value

Age(Range)	57.19 (36.85-74.92)	60.61 (44.38-91.38)	0.1692

Median Time to Relapse (years)	1.59 (0.23-4.91)

Median Followup (years)	6.47 (4.53-13.84)

Sex

 Male	21	22

 Female	7	15	0.2898

Smoking Status

 Yes	15	15

 No	13	22	0.3256

Tumor Stage11

 T2	6	15	0.1176

 T3	22	22

Fuhrman Grade

 Grade 1-2	7	22

 Grade 3-4	21	15	*0.0066


Matrix	Original (μg/kg)	Spiked (μg/kg)	Determined (μg/kg)	Recovery (%)1

Potato chips	53.2	100	151.2	98.0 ± 0.8

Chips (except potato chips)	<LOQ	100	97.7	97.7 ± 1.0

Biscuits	21.7	100	119.3	97.6 ± 2.7

French fries	35.7	100	135.3	99.5 ± 3.2

Chocolate products	<LOQ	100	96.7	96.7 ± 3.2

Breakfast cereals	9.7	100	117.3	107.6 ± 0.7

Tea products	13.3	100	107.8	94.5 ± 0.2

Seasoned laver	<LOQ	100	102.7	102.7 ± 3.7

Nuts products	<LOQ	100	105.0	105.0 ± 1.6


Subjects	Experimental (non obstructive CAD) group (n)	Control (obstructive CAD) Group (n)	P value*

Females	143	141	0.888

Males	99	101	0.906

Subjec	Experimental (non obstructive CAD) group (n)	Control (obstructive C	P val


Methods

Single-source

BIOGRID

String

PFAM BINARY

PFAM LOGE

Expr.

Seq. sim.

Multisource (data fusion)

Kernel fusion


	Odds Ratio	[95% Confidence Interval]	p-value

Age group	1.08	1.02 - 1.51	0.02

Family history of renal disease	1.12	0.76 - 1.45	0.05

School education	0.99	0.76 - 2.54	0.17

Physical inactivity	0.65	0.57 - 0.99	0.05

Hypertension	2.15	1.61 - 4.36	0.03

Diabetes	1.22	0.33 - 40.74	0.63

Obesity	1.33	1.05 - 1.98	0.04

	Odds Ratio	[95% Confidence Interval]	p-value

Obesity	1.33	1.05 - 1.98	0.04


Source of variation	df	SSD	VC	% total	P

1. Regions divided by rivers

 Among regions	4	168.349	0.507	23.87	<0.001

 Among populations within regions	44	356.604	1.075	50.60	<0.001

 Within populations	297	161.099	0.542	25.53	<0.001

 Total	345	686.052	2.125

2. Glaciated versus nonglaciated regions during Great Patagonian Glaciation

 Among regions	1	10.703	−0.013	−0.68	n.s.

 Among populations within regions	47	514.250	1.477	73.64	<0.001

 Within populations	297	161.099	0.542	27.04	<0.001

 Total	345	686.052	2.006


Amplified Region	Forward	Reverse

c-KIT exon 8	5'-CAGCAGTCTGACCTATGGC -3'	5'-GCTCAGCTCCTGGACAGAAA-3'

c-KIT exon 9	5'-GATTGATTGATTGATTTTCCTAG-3'	5'-GCAGGCAGAGCCTAAACATC-3'

c-KIT exon 11	5'-CATTTGTTCTCTACCCTAAGTGCT-3'	5'-GTTCCCTAAAGTCATTGTTACACG-3'

c-KIT exon 13	5'-CTGATTAAGTCGGATGCGGC-3'	5'-CAAGCACTGTCGCAATGG-3'

c-KIT exon 17	5'-ATAGCAGCATTCTCGTGTTG-3'	5'-AACTAAAATCCTTCACTGGACTG-3'

PDGFRA exon 12	5'-TTAATGGCTCTGATTGCTCAC-3'	5'-CACCCAGTGCTCATAACCTC-3'

PDGFRA exon 14	5'-ACTGGTTTTGGTTCCCACAG -3'	5'-CAATGATTCGCAGCAACG-3'

PDGFRA exon 18	5'-TAGCTCAGCCGTGGGTATG-3'	5'-CACATGAGCAGAGATGTCAGG-3'


Year range	No. records	Mortality (%)	Countries

An. arabiensis

Up to 2000 (first year = 1996)	3	Min 100	South Africa

Max 100

Mean 100

2001–2005	67	Min 75	Cameroon, Kenya, Madagascar, Mozambique, Nigeria, South Africa, Sudan, Tanzania

Max 100

Mean 95.6

2006–2010	218	Min 0	Burkina Faso, Cameroon, Chad, Ethiopia, Kenya, Mozambique, Senegal, Sudan, Tanzania, The Gambia, Uganda, Zambia, Zimbabwe

Max 100

Mean 79.3

2011–2015	161	Min 9	Ethiopia, Kenya, Malawi, Mali, South Africa, Senegal, Sudan, Tanzania, Uganda

Max 100

Mean 74.7

An. coluzzii

2001–2005	38	Min 19	Benin, Cameroon, Nigeria

Max 100

Mean 89.7

2006–2010	144	Min 0.9	Benin, Burkina Faso, Cameroon, Côte d’Ivoire, Ghana, Mali, Nigeria

Max 100

Mean 73.2

2011–2015	44	Min 1	Benin, Burkina Faso, Cameroon, Côte d’Ivoire, Mali, Mozambique, Liberia

Max 100

Mean 60.6

An. gambiae

Up to 2000 (first year = 1999)	10	Min 100	Zambia

Max 100

Mean 100

2001–2005	55	Min 27	Angola, Burundi, Cameroon, Equatorial Guinea, Mozambique, Nigeria, Uganda

Max 100

Mean 88.82

2006–2010	139	Min 0	Benin, Burkina Faso, Burundi, Cameroon, Congo, Ghana, Guinea, Kenya, Malawi, Mozambique, Uganda, Zambia

Max 100

Mean 75.2

2011–2015	48	Min 0	Cameroon, DRC, Ghana, Kenya, Mali, Tanzania, Uganda

Max 100

Mean 48.7

An. melas

All years (2005)	4	Min 100	Cameroon

Max 100

Mean 100

An. quadriannulatus

All years (2002)	1	Min 100	South Africa

Max 100

Mean 100


	Ukraine	Kazakhstan	Azerbaijan

	Respondentsa		Respondentsa		Respondentsa

	without BA	with BA	p-value	without BA	with BA	p-value	without BA	with BA	p-value

Valid N	871	70		693	237		817	115

Any co-morbidity, %	42.0	62.9	0.001	20.8	50.6	< 0.001	51.4	77.4	< 0.001


Primary antibodies	Secondary antibodies

Antibody	Company	Tissue	Dilution	Antibody	Company	Tissue	Dilution

Brn-3a	Santa Cruz	Retina	1:100	Donkey anti-goat Alexa Fluor 488	Dianova	Retina	1:1000

C1q	Quidel	Retina	1:2500	Donkey anti-goat IgG Cy3	Abcam	Retina	1:750

C3	Cedarlane	Retina	1:500	Goat anti-rabbit IgG Cy 3	Linaris	Retina	1:500

		Optic nerve	1:500			Optic nerve	1:500

C5b-9 (MAC)	Biozol	Retina	1:100	Donkey anti-mouse Dy Light 488	Dianova	Retina	1:250

		Optic nerve	1:100	Goat anti-mouse Alexa Flour 488	Invitrogen	Optic nerve	1:500

MASP2	Biozol	Retina	1:400	Donkey anti-rabbit Alexa Fluor 555	Invitrogen	Retina	1:400

		Optic nerve	1:100			Optic nerve	1:700

MBP	Millipore	Optic nerve	1:100	Goat anti-mouse Alexa Flour 488	Invitrogen	Optic nerve	1:500


Cookie acceptance

Low impulsivity

N

High impulsivity

N

Low risk

n

High risk

n


BaP		XPA	XPC	ERCC4	ERCC5	ERCC1

	RCC4	1.00	1.	1.00 ± 	1.	1.


Federal state	Percentage Av positive in total (x/y) [95% CI]	Percentage Cv positive in total (x/y) [95% CI]	Percentage Ea positive in total (x/y) [95% CI]	Percentage Av + Cv positive (x/y) [95% CI]	Percentage Av + Ea positive (x/y) [95% CI]	Percentage Cv + Ea positive (x/y) [95% CI]	Percentage Av + Cv + Ea positive (x/y) [95% CI]


 	 	Baseline	Two sessions	After pre-treatment	Start pain rehab treatment	Finish pain rehab treatment	6 months after T3

 	Abbr.	T0a	 	T1	T2a	T3a	T4

Covariates

Demographics patient	 	x

Primary outcome effect evaluation

Participation	USER-P	x	 	x	 	x	x

Secondary outcomes effect evaluation

Physical functioning/disability	PDI	x	 	 	x	x	x

Pain intensity	VAS	x	 	 	x	x	x

Main complaints	PSC	x	 	 	x	x	x

Drop-out/adherence	 	 	 	#	 	#

Self-efficacy/perceived competence	GSE	x	 	x	 	x	x

Pain-specific self-efficacy scale	CPSS_V2	x	 	x	 	x	x

Cost-effectiveness evaluation

Cost questionnaire	Tic-P	x	 	 	x	 	x

Productivity losses	SF-HLQ	x	 	 	x	 	x

Quality of life/health status	SF-36	x	 	 	x	x	x

Potential active ingredients MI

Stages of change	MPRCQ 2	x	 	x

MI integrity/fidelity	 	 	*

Potential moderators

Credibility and expectancy of the treatment	CEQ	x	 	x	x

Motivation	TMQ	x	 	x

Depression	BDI	x	 	 	x	x

Acceptance	AAQ-II	x	 	x	 	x

Flexible goal-adjustment	FGA	x	 	x	 	x

Process evaluation

Satisfaction with (pre-)treatment	 	 	 	x +

Client-centeredness	CCCQ	 	 	x

Feasibility	 	 	 	+

		Baseline	Two sessions

	Abbr.	T0a

Covariates

Demographics patient		x

Primary outcome effect evaluation

Participation	USER-P	x

Secondary outcomes effect evaluation

Physical functioning/disability	PDI	x

Pain intensity	VAS	x

Main complaints	PSC	x

Drop-out/adherence

Self-efficacy/perceived competence	GSE	x

Pain-specific self-efficacy scale	CPSS_V2	x

Cost-effectiveness evaluation

Cost questionnaire	Tic-P	x

Productivity losses	SF-HLQ	x

Quality of life/health status	SF-36	x

Potential active ingredients MI

Stages of change	MPRCQ 2	x

MI integrity/fidelity			*

Potential moderators

Credibility and expectancy of the treatment	CEQ	x

Motivation	TMQ	x

Depression	BDI	x

Acceptance	AAQ-II	x

Flexible goal-adjustment	FGA	x

Process evaluation

Satisfaction with (pre-)treatment

Client-centeredness	CCCQ

Feasibility

After pre-treatment	Start pain rehab treatment	Finish pain rehab treatment	6 months after T3

T1	T2a	T3a	T4

Covariates

Primary outcome effect evaluation

x		x	x

Secondary outcomes effect evaluation

	x	x	x

	x	x	x

	x	x	x

#		#

x		x	x

x		x	x

Cost-effectiveness evaluation

	x		x

	x		x

	x	x	x

Potential active ingredients MI

x

Potential moderators

x	x

x

	x	x

x		x

x		x

Process evaluation

x +

x

+


Activity limitation	No

Percentage with health indicatora	RR (95% CI)b

Health and well-being

Poor self-perceived health	2.2	1

Poor dental status	9.5	1

Pain or discomfort in musculoskeletal system	71.4	1

Headache	31.2	1

Fatigue	53.2	1

Dyssomnia	30.0	1

Psychological symptoms	29.9	1

Stress	14.0	1

Hypnotics/sedatives (prescription-only)	4.1	1

Hypnotics/sedatives (over-the-counter)	0.8	1

Analgesics (prescription-only)	11.9	1

Analgesics (over-the-counter)	34.7	1

Laxatives (prescription-only)	2.9	1

Laxatives (over-the-counter)	0.4	1

No sexual contact	26.2	1

Unsatisfied with sexual life	14.2	1


	Mean growth rate (SD) non-manual social class	Mean difference (95% CI) manual vs. non-manual social class

Birth length, cm Growth rate, cm/month	50.173 (1.642)	−0.439 (−0.599 to −0.279)

0–3 months	3.553 (0.241)	0.087 (0.016 to 0.158)

3–12 months	1.626 (0.136)	−0.002 (−0.030 to 0.026)

	Mean growth rate (SD) non-manual social class	Mean difference (95% CI) manual vs. non-manual social class

1–3 years	0.836 (0.071)	−0.015 (−0.026 to −0.005)

3–10 years	0.531 (0.035)	−0.008 (−0.013 to −0.003)


Method	Total number	Disorder number	Success rate

Subcutaneous injection of sesame oil	10	0	0.00%

Subcutaneous injection of DHEA	40	25	62.50%


PBMS	Comparison of PBMS parameters between study groups

Domains	control	intervention	range	p

 	Sub-domains

1 Attitude	3.5 (1.9)	3.0 (1.8)	0-9	.04*

 	a: expectations regarding outcomes	1.8 (0.6)	1.6 (0.6)	0-3	.001*

 	b: values of expected outcomes	1.8 (0.6)	1.8 (0.6)	0-3	.55

2 Social norm	2.1 (1.2)	1.7 (1.0)	0-9	.006*

 	a: assumed attitudes of important others	1.9 (0.6)	1.8 (0.7)	0-3	.28

 	b: motivation to comply with these norms	1.1 (0.4)	1.0 (0.4)	0-3	.004*

3 Control beliefs	3.2 (2.1)	2.9 (2.1)	0-9	.313

 	a: assumed facilitators or barriers	1.6 (0.7)	1.4 (0.8)	0-3	.14

 	b: perceived power of these factors	1.8 (0.6)	1.7 (0.7)	0-3	.42

Intention estimate	8.9 (4.1)	7.5 (4.4)	0-27	.04*

PBMS	Comparison of PBMS parameters between study groups

Domains	control	intervention	range	p

	Sub-domains

	a: assumed attitudes of important others	1.9 (0.6)	1.8 (0.7)	0-3	.28

	b: motivation to comply with these norms	1.1 (0.4)	1.0 (0.4)	0-3	.004*

3 Control beliefs	3.2 (2.1)	2.9 (2.1)	0-9	.313

	a: assumed facilitators or barriers	1.6 (0.7)	1.4 (0.8)	0-3	.14

	b: perceived power of these factors	1.8 (0.6)	1.7 (0.7)	0-3	.42

Intention estimate	8.9 (4.1)	7.5 (4.4)	0-27	.04*


	Estimates	Local adaptation contrasts

Measure (n)	Local scale (1)	Small scale (2)	Intermediate scale (3)	Large-scale (4)	1 vs. 2	1 vs. 3	1 vs. 4	1 + 2 vs. 3	1 + 2 vs. 4	1 + 2 + 3 vs. 4

Infectivity (n > 1076)	0.662	0.586	0.711	0.663	NS	NS	NS	NS	NS	NS


Groups	UACR (mg/g)	Total

Normal albuminuria (NA) (n = 35)	UACR < 30	n = 80

Microalbuminuria (MA) (n = 30)	30 ≤ UACR < 300

Clinical albuminuria (CA) (n = 15)	UACR ≥ 300

Normal group (NC) (n = 80)	Non-diabetic subjects	n = 80

Groups	UACR (mg/g)	Total

Microalbuminuria (MA) (n = 30)	30 ≤ UACR < 300	n = 80

Clinical albuminuria (CA) (n = 15)	UACR ≥ 300

Normal group (NC) (n = 80)	Non-diabetic subjects	n = 80


Factors related to attitude	Number

Location	396

Rural	306

Urban	90

Age	396

18–24 Years	24

25–34 Years	89

35–44 Years	135

45–54 Years	115

55–60 Years	33

Gender	396

Male	73

Female	323

Caste	396

Dalit	35

Non Dalit	361

Provider’s Type	396

Dr/HA/AHW	87

Nurse/ANM	94

FCHVs	215


	All patients	CN-AML patients

Final model	HR	95% CI	P-value	HR	95% CI	P-value

Presence of unfavorable karyotype	2.54	1.56–4.12	<0.001	NA	NA	NA

Presence of SNP-A lesion(s)	2.25	1.39–3.65	0.001	2.38	1.28–4.43	0.006

Presence of NPM1 mutation	1.12	0.67–1.87	0.68	NA	NA	NA

Presence of EVI1 overexpression	1.63	0.87–3.06	0.12	NA	NA	NA

Presence of DNMT3A mutation	NA	NA	NA	1.91	1.02–3.56	0.042

Presence of IDH2R140 mutation	NA	NA	NA	0.38	0.09–1.63	0.19

Randomization in the GO arm	0.75	0.49–1.13	0.17	0.51	0.27–0.98	0.043

	All patients

Final model	HR

Presence of unfavorable karyotype	2.54

Presence of SNP-A lesion(s)	2.25

Presence of NPM1 mutation	1.12

Presence of EVI1 overexpression	1.63

Presence of DNMT3A mutation	NA

Presence of IDH2R140 mutation	NA

Randomization in the GO arm	0.75


Closest taxon 	Log inactivation	Resistance (log10(CFU·100 mL−1))

Maximum	Treatment	Minimum 	Treatment

A. hydrophila	0.84	10.43	TI 30 mg·L−g/15 min	11.27	TII 20 mg·L−g/0 min

E. coli	1.31	10.15	TI 8 mg·L−g/30 min	11.45	TIII 8 mg·L−g/30 min

E. coli PD3	1.86	10.62	TIII 30 mg·L−g/0 min	12.48	TI 30 mg·L−g/0 min

E. coli BL21	0.80	10.37	TI 8 mg·L−g/0 min	11.18	TII 20 mg·L−g/0 min

E. cloacae	0.81	10.38	TIII 30 mg·L−g/30 min	11.19	TIII 8 mg·L−g/0 min


Characteristics

Gender

Male

Female

Age (years)

<70

≥70

Location

Colon

Rectum

Stage

I

II

III

IV

Differentiation

Well/moderately

Poorly


Characteristics	Synbiotics (n = 43)	Placebo (n = 42)	p-Value

Sex *

Ma	7 (16	5 (11.9	0.5


Phylogenetic Group	A	B

A1	A2	A3

Predicted CDS	EhV-84	EhV-86	EhV-88	EhV-145	EhV-164	EhV-201	EhV-203	EhV-207	EhV-208	EhV-99B1	EhV-202	EhV-18	EhV-156

hypothetical protein	27	3	4	7	8	4	4	9	9	6	18	9	6

putative endonuclease										2

putative membrane protein		2		1	1					4

putative transposase										1

putative DUF814 domain containing protein										1

zinc finger protein							1

putative ribonuclease												1	1

glycosyltransferase family 29 (sialyltransferase)												1	1

Total	27	5	4	8	9	4	5	9	9	15	18	11	8

Phylogenetic Group	A

A1

Predicted CDS	EhV-84	EhV-86	EhV-88	EhV-145

hypothetical protein	27	3	4	7

putative endonuclease

putative membrane protein		2		1

putative transposase

putative DUF814 domain containing protein

zinc finger protein

putative ribonuclease

glycosyltransferase family 29 (sialyltransferase)

Total	27	5	4	8


	Exposure time [min]	HIV-1 titer [TCID50/ml] after exposure to uncoated and coated coverslip and after washing with 0.49 ml of PBS	HIV-1 titer reductiona	p-valueb

Coverslip #1	Coverslip #2	Coverslip #3

Uncoated coverslip	5	3981	3981	3981	-	-

20	3981	1000	3981	-	-

Coated coverslip by heat polymerization	5	251	1259	1000	79 %	<0.001

20	316	251	316	90 %	<0.05

Coated coverslip by photopolymerization	5	63	63	63	98 %	<0.001

20	0	20	0	99.8 %	<0.05

	Exposure time [min]	HIV-1 titer [TCID50/ml] after exposure to uncoated and coated coverslip and after washing with 0.49 ml of PBS	HIV-1 titer reductiona	p-valueb

Coverslip #1	Coverslip #2	Coverslip #3

Coated coverslip by heat polymerization	5	251	1259	1000	79 %	<0.001

20	316	251	316	90 %	<0.05

Coated coverslip by photopolymerization	5	63	63	63	98 %	<0.001

20	0	20	0	99.8 %	<0.05


Gender	Functional dyspepsia	Organic dyspepsia	Total

Male	72 	40	112

Female	120	64	184

Total	192	104	296

Gender	Functional dyspepsia	Organic dyspepsia	Total

Female	120	64	184

Total	192	104	296


Names	Sequence (5′–3′)	Tm (°C)	Mw

Osa-miR156	UGA CAG AAG AGA GUG AGC AC	57.3	6279

(Biotin)-miD156rk	(Biotin)-A CGT GCT CAC TCT CTT CTG TCA	60.5	6587+

(DIG)-miD156rk	(DIG)-A CGT GCT CAC TCT CTT CTG TCA	60.5	6587+

miD156	TGA CAG AAG AGA GTG AGC AC	57.3	6201+

miD156(−1)	TGA gAG AAG AGA GTG AGC AC	55.4	6241

miD156(−3)	aGA CAG gAG gGA GTG AGC AC	57.4	6242

miD156(−5)	aGA CAG gAG tGA GTc AGC gC	59.5	6193+

let-7a	UGA GGU AGU AGG UUG UAU AGU U	46.1	7244

(Biotin)-let-7rk	(Biotin)-ACA ACT ATA CAA CCT ACT ACC TCA	52.6	7166+

(DIG)-let-7rk	(DIG)-ACA ACT ATA CAA CCT ACT ACC TCA	52.6	7166+

Names	Sequence (5′–3′)

Osa-miR156	UGA CAG AAG AGA GUG AGC AC

(Biotin)-miD156rk	(Biotin)-A CGT GCT CAC TCT CTT CTG TCA

(DIG)-miD156rk	(DIG)-A CGT GCT CAC TCT CTT CTG TCA

miD156	TGA CAG AAG AGA GTG AGC AC

miD156(−1)	TGA gAG AAG AGA GTG AGC AC

miD156(−3)	aGA CAG gAG gGA GTG AGC AC

miD156(−5)	aGA CAG gAG tGA GTc AGC gC

let-7a	UGA GGU AGU AGG UUG UAU AGU U

(Biotin)-let-7rk	(Biotin)-ACA ACT ATA CAA CCT ACT ACC TCA

(DIG)-let-7rk	(DIG)-ACA ACT ATA CAA CCT ACT ACC TCA


Test microorganisms	Inhibition zone diameter (mm) ¥	MIC (μg/ml)	MIC of penicillin (μg/ml)

Bacillus subtilis MTCC 736	25 ± 1.0	2.0	0.5

Bacillus circulans MTCC 8074	23 ± 1.2	3.0	0.5

Bacillus megaterium MTCC 8075	26 ± 1.5	2.0	0.5

Staphylococcus aureus MTCC 96	31 ± 0.9	0.5	0.25

Staphylococcus aureus (Clinical isolate)	30 ± 0.9	0.5	0.25

Micrococcus luteus MTCC 2987	25 ± 1.3	2.0	0.5

Mycobacterium phlei MTCC 1724	25 ± 1.0	2.0	0.5

Mycobacterium smegmatis MTCC 6	21 ± 0.5	3.0	1.0

Escherichia coli MTCC 739		ND	ND

Klebsiela pneumoniae MTCC 3040		ND	ND

Pseudomonas aeruginosa MTCC 2453		ND	ND


Parameter	All subjects%	M%	F%	P

Living with one’s family	63.1	78.6	51.5	<0.001**

Regular exercise	61.7	84.1	44.5	<0.001**

Smokes cigarettes	19.7	13.6	24.2	0.023

Consumed alcoholic beverages	36.1	39.3	33.7	NS

Experienced drugs	16.4	17.0	15.9	0.01*

Parameter	All subjects%	M%	F%	P

Experienced drugs	16.4	17.0	15.9	0.01*


	SOD (% of Control)	Catalase (% of Control)	Glutathione Reductase (% of Control)	Glucose-6-phosphate Dehydrogenase (% of Control)

BDP 2 μg	135 ± 2	136 ± 3	134 ± 3	132 ± 3

BDP 5 μg	105 ± 3	102 ± 4	103 ± 3	127 ± 4

BDP 10 μg	192 ± 5	204 ± 7	183 ± 2	237 ± 2


Use diversity	D. sisso	A. modesta	A. nilotica	C. desidua	M. boxifolia	Z. nummularia	M. nigra	M. azidarach	W. coagulans	R. stricta	Total	Rank

Construction	5	2	3	1	2	3	4	3	1	1	25	2

Agriculture	4	2	2	3	2	2	2	1	1	1	20	5

Firewood	3	4	3	2	3	2	3	2	2	2	26	1

Fodder	2	3	3	2	2	3	3	2	3	1	24	3

Medicinal	1	3	3	3	2	2	1	2	3	3	23	4

Total	15	14	14	11	11	12	13	10	10	8

Rank	1	2	2	5	5	4	3	6	6	7

Market price in US$/Kg	0.6	0.5	0.5	0.2	0.53	0.4	0.4	0.2	0.9	0.8

Use diversity	D. sisso	A. modesta	A. nilotica	C. desidua	M. boxifolia	Z. nummularia	M. nigra	M. azidarach	W. coagulans	R. stricta	Total	Rank

Firewood	3	4	3	2	3	2	3	2	2	2	26	1

Fodder	2	3	3	2	2	3	3	2	3	1	24	3

Medicinal	1	3	3	3	2	2	1	2	3	3	23	4

Total	15	14	14	11	11	12	13	10	10	8

Rank	1	2	2	5	5	4	3	6	6	7

Market price in US$/Kg	0.6	0.5	0.5	0.2	0.53	0.4	0.4	0.2	0.9	0.8


Group	n	Expression of ELF

High	Low

Normal liver tissues	20	20(100.0%)	0(0.0%)

Adjacent tissues*	84	65(77.4%)	19(22.6%)

HCC tissues*#	84	40(47.6%)	44(52.4%)


Externality category	UK	USA	Germany

€ million	€ per kg a.i.	€ million	€ per kg a.i.	€ million	€ per kg a.i.

Pesticides in drinking water	217	9.06	851	2.00	137	5.15

Pollution incidents, fish deaths and monitoring costs	15	0.68	122	0.29	39	1.47

Biodiversity and wildlife losses	23	1.01	157	0.37	5	0.18

Cultural, landscape and tourism	90	3.98	nd	nd	nd	nd

Bee colony losses	2	0.08	109	0.26	2	0.04

Acute effects of pesticides on human health	2	0.08	127	0.30	21	0.80

Totals	349	15.5	1366	3.2	202	7.6


	ABTS (μmol/mL)	DPPH (μmol/mL)	FRAP (mmol/mL)

Raw hydrolysate supernatant	5.34 ± 1.29	0.18 ± 0.08	0.60 ± 0.04

After ultrasound treatment	5.92 ± 0.96	0.27 ± 0.07	0.73 ± 0.04

After autoclaving	7.03 ± 1.34	0.24 ± 0.05	0.79 ± 0.05


ADAPT-ITT phase	Methodology

1. Assessment	Conducted focus groups/needs assessment with Community Advisory Board (CAB)

2. Decision	Decision regarding type of intervention was pre-determined by evidence base; however, decisions regarding characteristics of the intervention (equipment and study structure) were made.

3. Administration	Theater testing was conducted during the CAB focus groups with patient stakeholders prior to intervention implementation.

4. Production	A draft of the tailored intervention was presented to the CAB for further feedback and approval.

5. Topical experts	The study team specifically recruited topical experts for CAB membership; see Table 2.

6. Integration	CAB input was integrated into the final adapted version of the intervention; the telehealth software company revised the software to reflect CAB recommendations.

7. Training	Both clinical and installation experts received training with regard to study structure and equipment use.

8. Testing	A pilot test of the intervention was conducted with 10 patients to identify “hands-on” challenges requiring adaptation; a focus group was then held with 4 of those patients to further explore these challenges and solutions


	MRI (+)	MRI (−)	p Value

Systematic cores n = 2696 (A)	Targeted cores n = 345 (B)	Systematic cores n = 3542 (C)	A vs B	A vs C	B vs C

Cores of cancer, n (%)	333	(12.3)	108	(31.3)	355	(10.0)	<0.0001	0.004	<0.0001


	Healthy Controls (n = 50)	Patients (n = 50)	p-Value

Gender female—n (%)	15 (30.0%)	17 (34.0%)	0.83

Age—median years (p 25–75)	59 (50–68)	60 (51–69)	0.47


PFT and Polygraphy (during withdrawal)	n = 15

ODI ≥ 4% (n/h)	42.1 ± 39.5


No.	Species	GenBank accession No.	Locality	Voucher ID

1	Cyrtodactylus badenensis	KF929505	Vietnam, Tay Ninh Prov.	KIZ13689

2	C. bansocensis	KU175573	Laos, Khammouane Prov.	VNUF–R.2015.20

3	C. bansocensis	KU175574	Laos, Khammouane Prov.	NUOL-R-2015.21

4	C. bobrovi	KT004368	Vietnam, Hoa Binh Prov.	IEBR-A.2015.30

5	C. bobrovi	KT004369	Vietnam, Hoa Binh Prov.	VNMN-A.2015.61

6	C. calamei	KX064043	Laos, Khammouane Prov.	NUOL-R-2015.22

7	C. calamei	KX064044	Laos, Khammouane Prov.	VNUF-R.2015.28

8	C. cryptus	KF169971	Vietnam, Quang Binh Prov.	PNKB3

9	C. cryptus	KF169972	Vietnam, Quang Binh Prov.	PNKB4

10	C. cryptus	KX064038	Laos, Khammouane Prov.	VNUF-R.2014.69

11	C. elok	HM888478	Malaysia	ZMMU-RAN1991

12	C. darevskii	HQ967221	Laos, Khammouane Prov.	ZISP-FN256

13	C. darevskii	HQ967223	Laos, Khammouane Prov.	ZISP-FN223

14	C. hinnamnoensis	KX064045	Laos, Khammouane Prov.	IEBR-A.2013.89

15	C. hinnamnoensis	KX064046	Laos, Khammouane Prov.	IEBR-A.2013.90

16	C. hinnamnoensis	KX064047	Laos, Khammouane Prov.	VNUF-R.2015.11

17	C. hinnamnoensis	KX064048	Laos, Khammouane Prov.	VNUF-R.2015.3

18	C. hinnamnoensis	KX064049	Laos, Khammouane Prov.	NUOL-R-2015.9

19	C. lomyenensis	KJ817436	Laos, Khammouane Prov.	IEBR-KM2012.54

20	C. lomyenensis	KP199942	Laos, Khammouane Prov.	IEBR-KM2012.52

21	C. interdigitalis	KX077901	Laos, Khammouane Prov.	VNUF-R.2014.50

22	C. jaegeri	KT004364	Laos, Khammouane Prov.	IEBR-A.2013.55

23	C. jaegeri	KT004365	Laos, Khammouane Prov.	NUOL-R.2013.1

24	C. jaegeri	KT004366	Laos, Khammouane Prov.	VFU-TK914

25	C.cf. jarujini	KX077907	Laos, Bolikhamxay Prov.	VNUF-R.2015.7

26	C. khammouanensis	HM888467	Laos, Khammouane Prov.	ZISP-FN191

27	C. khammouanensis	HM888469	Laos, Khammouane Prov.	ZISP-FN257

28	C. kingsadai	KF188432	Vietnam, Phu Yen Prov.	IEBR-A.2013.3

29	C.cf. martini	KF929537	China, Yunnan Prov.	KIZ201103

30	C. multiporus	HM888472	Laos, Khammouane Prov.	ZISP-FN3

31	C. multiporus	HM888471	Laos, Khammouane Prov.	ZISP-FN2

32	C. otai	KT004370	Vietnam, Hoa Binh Prov.	IEBR-A.2015.26

33	C. otai	KT004371	Vietnam, Hoa Binh Prov.	IEBR-A.2015.27

34	C. puhuensis	KF929529	Vietnam, Thanh Hoa Prov.	KIZ11665

35	C.aff. pulchellus	HQ967202	Malaysia	ZMMU-R-12643-3

36	C.aff. pulchellus	HQ967203	Malaysia	ZMMU-R-12643-4

37	C. pageli	KJ817431	Laos, Vientiane Prov.	ZFMK91827

38	C. pageli	KX077902	Laos, Vientiane Prov.	NQT2010.36

39	C. pageli	KX077903	Laos, Vientiane Prov.	NQT2010.37

40	C. phongnhakebangensis	KF929526	Vietnam, Quang Binh Prov.	PNKB2011.30

41	C. phongnhakebangensis	KF929527	Vietnam, Quang Binh Prov.	PNKB2011.32

42	C. pseudoquadrivirgatus	KF169963	Vietnam, Thua Thien - Hue Prov.	ITBCZ3001

43	Cyrtodactylussp. 1	KP199949	Vietnam, Da Nang, Ba Na	ZMMU-R-13095-2

44	C. quadrivirgatus	HM888465	Malaysia	ZMMU-RAN1989

45	C. quadrivirgatus	HM888466	Malaysia	ZMMU-RAN1990

46	C. roesleri	KF929532	Vietnam, Quang Binh Prov.	PNKB2011.34

47	C. roesleri	KF929531	Vietnam, Quang Binh Prov.	PNKB2011.3

48	C. rufford	KU175572	Laos, Khammouane Prov.	VFU-R.2015.14

49	C. sommerladi	KX064039	Laos, Khammouane Prov.	IEBR-A.2015.37

50	C. sommerladi	KX064040	Laos, Khammouane Prov.	VNUF-R.2013.22

51	C. sommerladi	KX064041	Laos, Khammouane Prov.	VNUF-R.2013.87

52	C. sommerladi	KX064042	Laos, Khammouane Prov.	IEBR-A.2015.39

53	C. spelaeus	KP199947	Laos, Vientiane Prov.	ZMMU-R-13980-3

54	C. spelaeus	KP199948	Laos, Vientiane Prov.	ZMMU-R-13980-1

55	C. soudthichaki	KX077904	Laos, Khammouane Prov.	NUOL-R-2015.5

56	C. soudthichaki	KX077905	Laos, Khammouane Prov.	VFU-R.2015.18

57	C. soudthichaki	KX077906	Laos, Khammouane Prov.	IEBR-A.2015.34

58	C. teyniei	KJ817430	Laos, Khammouane Prov.	IEBR-KM2012.77

59	C. teyniei	KP199945	Laos, Khammouane Prov.	IEBR-KM2012.77

60	C. vilaphongi	KJ817434	Laos, Luang Prabang Prov.	NUOL-R-2013.5

61	C. vilaphongi	KJ817435	Laos, Luang Prabang Prov.	IEBR-A.2013.103

62	C. wayakonei	KJ817438	Laos, Luang Nam Tha Prov.	ZFMK91016

63	C. wayakonei	KP199950	Laos, Luang Nam Tha Prov.	ZMMU-R-13981-1

64	Cyrtodactylus thathomensissp. nov.	MG791873	Laos, Xiangkhouang Prov.	ZMMU-R-14919-1

65	Cyrtodactylus thathomensissp. nov.	MG791874	Laos, Xiangkhouang Prov.	ZISP 29731

66	Cyrtodactylus thathomensissp. nov.	MG791875	Laos, Xiangkhouang Prov.	ZMMU R-15384


Clinicopathologic Characteristics

Age at diagnosis (years)

 Median (range)	62 (30–80)

Histology (n (%))

 Ductal	44 (90%)

 Lobular	5 (10%)

Histologycal grade (n (%))

 I and II	39 (80%)

 III	10 (20%)

UICC stage (n (%))

 IIB	6 (12%)

 IIIA + IIIB	11 (22%)

 IV	32 (65%)

ER status (n (%))

 positive	49 (100%)

 negative	0 (0%)

PR status(n (%))

 positive	33 (67%)

 negative	16 (33%)

HER2 status (n(%))

 positive	8 (16%)

 negative	41 (84%)


Univariate Analysis of log(MIF) over Time

	Den DF	F Value 	P-Value	Slope Estimator	SD (Estimator)

Continuous variable

Age	47.7	0.03	0.8604	−0.00239	0.01351

BMI	47.8	0.34	0.5605	−0.02082	0.03551

Baseline MIF, logarithmized	42.2	11.44	0.0016 *	0.4456	0.1317

Categorical variable

Gender (male)	48	0.07	0.7942	−0.0857	0.3267

Endovascular repair	48.2	0.01	0.9172	−0.02937	0.2809

Continuous variable (repeated measurements)

Serum creatinine	171	3.11	0.0796	0.2094	0.1187

Apache II	137	12.92	0.0005 *	0.04273	0.01189


	Men/Boys	Women/Girls

Caritas population	Barcelona residents	Caritas population	Barcelona residents

Direct Assistance Services	Housing Mediation Service	Overall	Deprived social classes (IV and V)	Direct Assistance Services	Housing Mediation Service	Overall	Deprived social classes (IV and V)

Adults

 Regular or poor self-reported health	24.4	45.8	11.2	12.8	53.1	60.3	15.3	20.5

 Quality of life, below the median score in Cáritas	35.6	51.4	5.6	4.4	47.7	58.9	8.3	13.1

 Poor mental health (Goldberg-12)	62.2	75.0	11.5	12.1	66.9	72.6	15.2	17.4

 Self-reported depression or anxiety the previous year	57.8	70.8	5.8	6.8	63.8	86.1	9.2	10.6

 Consumption of tranquilizers, antidepressants, or sleeping pills the previous 2 days	6.7	18.1	6.7	8.3	15.4	30.1	15.7	13.8

 Self-reported migraine or frequent headaches during the previous year	28.9	38.9	3.6	3.6	62.3	65.8	8.5	7.9

 Self-reported backache during the previous year	37.8	63.4	12.0	15.8	73.9	83.6	19.2	18.9

 6 or less daily mean hours of sleep (working days)	45.5	56.9	22.1	22.1	53.1	61.1	24.9	30.6

Children

 Regular or poor health status	22.7	7.1	0.9	NE	22.9	22.0	1.7	NE

 Poor mental health (SDQ questionnaire)	61.3	45.2	3.1	NE	37.5	25.0	5.1	NE

 Recurrent otitis during the previous year	20.5	19.0	3.6	NE	31.9	19.5	1.6	NE

 Not having had breakfast everyday before leaving home	15.9	26.2	6.4	15.4	20.8	22.0	8.4	14.5

	Men/Boys	Women/Girls

Caritas population	Barcelona residents	Caritas population	Barcelona residents

Direct Assista	Housing Mediation	Ov	Depri		Housing Media	Ove	Deprived social classes (IV an

	nce Services	 Service	erall	ved social classes (IV and V)	Direct Assistance Services	tion Service	rall	d V)

Adults

Regular or poor self-reported health	24.4	45.8	11.2	12.8	53.1	60.3	15.3	20.5

Quality of life, below the median score in Cáritas	35.6	51.4	5.6	4.4	47.7	58.9	8.3	13.1

Poor mental health (Goldberg-12)	62.2	75.0	11.5	12.1	66.9	72.6	15.2	17.4

Self-reported depression or anxiety the previous year	57.8	70.8	5.8	6.8	63.8	86.1	9.2	10.6

Consumption of tranquilizers, antidepressants, or sleeping pills the previous 2 days	6.7	18.1	6.7	8.3	15.4	30.1	15.7	13.8

Self-reported migraine or frequent headaches during the previous year	28.9	38.9	3.6	3.6	62.3	65.8	8.5	7.9

Self-reported backache during the previous year	37.8	63.4	12.0	15.8	73.9	83.6	19.2	18.9

6 or less daily mean hours of sleep (working days)	45.5	56.9	22.1	22.1	53.1	61.1	24.9	30.6

Children

Regular or poor health status	22.7	7.1	0.9	NE	22.9	22.0	1.7	NE

Poor mental health (SDQ questionnaire)	61.3	45.2	3.1	NE	37.5	25.0	5.1	NE

Recurrent otitis during the previous year	20.5	19.0	3.6	NE	31.9	19.5	1.6	NE

Not having had breakfast everyday before leaving home	15.9	26.2	6.4	15.4	20.8	22.0	8.4	14.5


GENE	Sense	Anti-sense	Product

ABCA1	5’-AGGCCCAGACCTGTAAATGC-3’	5’-CTCACCAACCTTGCCAACTTC-3’	450 bp

SREBP2	5’-CAGACGCCAAGATGCACAAG-3’	5’-TGGCTCATCTTTGACCTTTGC-3’	323 bp

CYP7A1	5’-CATTTGGGCACAGAAGCATTG-3’	5’-AGGCAGCGGTCTTTGAGTTAG-3’	174 bp

NR1H3 (LXR α)	5’-AAGAAACTGAAGCGGCAAGA-3’	5’-AGCAATGAGCAAGGCAAACT-3’	555 bp

PRKAA2 (AMPK α2)	5’-TCAATCGTTCTGTCGCCAC-3’	5’-ATACGGTTTGCTCTGACTTCG-3’	530 bp

HMGCR	5’-CTCCGCAGGCTATTTGTTCAG-3’	5’-GCTAAGAGCGTTCGTGGGTC-3’	620 bp

GAPDH	5’-ACTCCTCCACCTTTGACGCTG-3’	5’-CTCTCTTCCTCTTGTGCTCTTGC-3’	182 bp

GENE	Sense	Anti-sense	Product

GAPDH	5’-ACTCCTCCACCTTTGACGCTG-3’	5’-CTCTCTTCCTCTTGTGCTCTTGC-3’	182 bp


District	Percentage (%) scores of:

Total points	Reports	Management of supplies	Information management	Meetings	Technical support	Referrals

Nadowli	58.9	77.4	71.7	69.7	33.6	42.5	58.6

Wa Municipal	73.3	90.3	87.5	88.5	51.0	61.1	61.6

Wa East	54.1	74.5	78.9	74.8	39.2	0.0	57.2

Wa West	60.1	64.1	66.8	74.0	43.1	0.0	52.6

Lawra	30.0	46.6	30.6	28.8	26.0	12.9	35.2


Parameter	Estimate	Std. error	p-Value

Intercept	−3.96	2.90	0.18

Stimulation	1.46	0.74	0.05

Time	0.39	0.10	<0.01

Quadrant	3.27	0.74	<0.01

Sequence	5.99	0.98	<0.01

Time × sequence	−0.18	0.07	0.01

Variance components		SD

Subjects		6.72

Parameter	Estimate	Std. error

Intercept	−3.96	2.90

Stimulation	1.46	0.74

Time	0.39	0.10

Quadrant	3.27	0.74

Sequence	5.99	0.98

Time × sequence	−0.18	0.07

Variance components		SD

Subjects		6.72


Manufacturer	Name of Product	Vaccine Type	Adjuvant	Produced in	Age Recommended

Abbot healthcare	Trivalent: Influvac Imuvac	Inactivated	None	Egg	From 6 months

AstraZeneca	Quadrivalent: Fluenz Tetra (Flumist quadrivalent) Trivalent: Fluarix Alpharix Influsplit	Live attenuated	None	Egg	From 24 months to 17 years Trivalent: From 6 months

GlaxoSmithKline	Quadrivalent: Fluarix Tetra Alpharix Tetra Influsplit Tetra	Inactivated/split	None	Egg	From 3 years

Novartis	Trivalent: Agrippal Fluvirin Fluad	Inactivated/subunit	None None Squalene (MF59)	Egg	From 6 years From 4 years From 65 years

Pfizer/CSl Australia	Trivalent: Afluria Enzira	Inactivated	None	Egg	From 5 years

Sanofi Pasteur	Trivalent: Vaxigrip Intanza 9 μg Intanza 15μg	Inactivated	None	Egg	From 6 months From 18-59 years From 60 years

Manufacturer	Name of Product	Vaccine Type	Adjuvant	Produced in	Age Recommended

GlaxoSmithKline	Quadrivalent: Fluarix Tetra Alpharix Tetra Influsplit Tetra	Inactivated/split	None	Egg	From 3 years

Novartis	Trivalent: Agrippal Fluvirin Fluad	Inactivated/subunit	None None Squalene (MF59)	Egg	From 6 years From 4 years From 65 years

Pfizer/CSl Australia	Trivalent: Afluria Enzira	Inactivated	None	Egg	From 5 years

Sanofi Pasteur	Trivalent: Vaxigrip Intanza 9 μg Intanza 15μg	Inactivated	None	Egg	From 6 months From 18-59 years From 60 years


Variable	Bacteremic	Non-bacteremic	p value

(n = 38)	(n = 106)

Age under 50 years	9 (23.7)	25 (23.6)	1.00

Age 50–64 years	13 (34.2)	31 (29.2)	0.68

Variable	Bacteremic	Non-bacteremic	p value

(n = 38)	(n = 106)

Age 65–74 years	6 (15.8)	27 (25.5)	0.27

Age over 75 years	10 (26.3)	23 (21.7)	0.65

Immunocompromised	7 (18.4)	11 (10.4)	0.25

Shock at ICU admission	23 (60.5)	63 (59.4)	1.00

Invasive mechanical ventilation	28 (73.7)	78 (73.6)	1.00

Acute kidney injury	17 (44.7)	43 (40.6)	0.70

Rapid radiographic spread	24 (63.2)	53 (50.0)	0.19

Combined therapy	34 (89.5)	86 (81.1)	0.31

Antibiotic initiated 0 to 3 hours	18 (47.4)	55 (51.9)	0.71

ICU mortality	11 (28.9)	26 (24.5)	0.67


Monitoring dates	Albendazole treated risk cattle cohort	Placebo treated risk cattle cohort

	Trypanosome cases	Cattle-months	IDR	95 % CI5	Trypanosome cases	Cattle-months	IDR	95 % CI5

Intervention area

Jun - Nov 2008	1	247.6	0.004	0.000-0.020	8	293.6	0.031	0.010-0.050

Nov 2008 – Feb 2009	1	192.8	0.005	0.000-0.026	0	209.2	0	0

Feb – Jun 2009	1	240.3	0.004	0.000-0.021	1	256.3	0.004	0.000-0.019

Jun – Nov 2009	0	517.5	0	0	0	493.1	0	0


Method 1	Method 2	Method 3	Method 4	Method 5


Study	Measure	Assessed variable	Time of assessment

Study 1 cultural validity	Cultural Relevance Questionnaire (CRQ)	Culturally adapted internet-delivered treatment	Completed by experts and users before the trial.

Study 2 efficacy trial	Patient Health Questionnaire (PHQ-9)	Depression symptoms	Baseline, post-treatment and follow- up

Generalised Anxiety Disorder 7 (GAD-7).	Anxiety symptoms	Baseline, post-treatment and follow- up

Sociodemographic & Clinical History Questionnaire	Gender, age, marital status, education, occupation, socioeconomic status and clinical history	Baseline

Helpful and Hindering Aspects of Treatment (HAT)	Helpful and hindering aspects of treatment	After each session

Satisfaction with Treatment (SAT)	Satisfaction with therapy	Post-treatment

Study	Measure	Assessed variable	Time of assessment

Study 1 cultu	Cultural R	Culturally ada	Complet

Study	Measure	Assessed variable	Time of assessment

ral validity	elevance Questionnaire (CRQ)	pted internet-delivered treatment	ed by experts and users before the trial.

Study 2 efficacy trial	Patient Health Questionnaire (PHQ-9)	Depression symptoms	Baseline, post-treatment and follow- up

Generalised Anxiety Disorder 7 (GAD-7).	Anxiety symptoms	Baseline, post-treatment and follow- up

Sociodemographic & Clinical History Questionnaire	Gender, age, marital status, education, occupation, socioeconomic status and clinical history	Baseline

Helpful and Hindering Aspects of Treatment (HAT)	Helpful and hindering aspects of treatment	After each session

Satisfaction with Treatment (SAT)	Satisfaction with therapy	Post-treatment


Author, date	Conclusions	Contributions

Levy et al., 2009 [1]	AUT is not a monogenic disorder, in many individuals may be the result of a complex amalgam of multiple simultaneous genetic variations, and present morphological and functional brain abnormalities.	Highlights the importance of understanding biological markers, patterns of cortical organization and connectivity in advancing the treatment of AUT.

Baron-Cohen et al., 2000 [19]	Unlike those with TD in ToM tests, patients with AS or AUT do not show activation of the amygdala when making mentalistic inferences from the eyes. The amygdala may be one of many abnormal neural regions in AUT.	Highlights the role of the amygdala in the symptoms of ASD.

Castelli et al., 2002 [20]	The physiological cause for the mentalizing dysfunction in AUT can be a bottleneck in the interaction between perceptual processes of higher and lower order.	Relates the difficulties in understanding socially relevant movements in AUT to information processing in the visual cortex.

Brunet et al., 2000 [21]	Attribution of intentions to others is associated with a complex brain activity involving the right medial prefrontal cortex when a nonverbal task is used.	Presents data that validate hypothesis of abnormal brain activation in patients with impaired mentalizing.

Castelli et al., 2000 [22]	The regions responsible for processing information about intentions and the ability to make inferences about the mental states of others may have evolved from the ability to make inferences about the actions of other creatures.	Suggests evolutionary history for the abilities that make ToM.

Pierce et al., 2001 [23]	Compared to typical individuals, autistic "see" faces using different neural systems, unique to each individual.	Experiential factors play an important role in the development of the fusiform facial area, related to the processing faces.

Scholz et al., 2009 [24]	There are neighboring but distinct regions in the right temporo-parietal junction involved in ToM and orientation of attention.	Identifies difficulties in the investigation of brain functions that occupy regions close to each other or overlapping.

Johnson et al., 2007 [25]	There is involvement of frontal and parietal attentional networks and sub-cortical excitatory systems in ADHD and a prefrontal cortex dysfunction in children with HFA.	Provides detailed evidence of dysfunction in sustained attention in ADHD significantly higher than in HFA.

Kana et al., 2007 [26]	The neural circuit linked to inhibition in individuals with ASD is atypically activated and is less synchronized, leaving inhibition to be accomplished by strategic control rather than automatically.	Identifies dysfunction in inhibitory cortical level, being disorganized and desynchronized.

Schultz et al., 2000 [27]	Individuals with ASD demonstrate during facial discrimination, a pattern of brain activity consistent with strategies based on characteristics or traits more typical of the perception of non-facial objects.	Highlights possible dysfunction in processing stimuli related to biological and inanimate objects in ASD.

Dapretto et al., 2006 [28]	A dysfunctional mirror neuron system may underlie the social deficits of autism.	Substantiates hypothesis of the importance of mirror neurons in the development of social functions.

Jones et al., 2008 [29]	The behavior of eye contact is already noticeably compromised in children two years of age with ASD, accompanying the person with autism for life.	Subsidizes and highlights the importance of early diagnosis of ASD.

Author, date	Conclusions

Levy et al., 2009 [1]	AUT is not a monogenic disorder, in many individuals may be the result of a complex amalgam of multiple simultaneous genetic variations, and present morphological and functional brain abnormalities.

Baron-Cohen et al., 2000 [19]	Unlike those with TD in ToM tests, patients with AS or AUT do not show activation of the amygdala when making mentalistic inferences from the eyes. The amygdala may be one of many abnormal neural regions in AUT.

Castelli et al., 2002 [20]	The physiological cause for the mentalizing dysfunction in AUT can be a bottleneck in the interaction between perceptual processes of higher and lower order.

Brunet et al., 2000 [21]	Attribution of intentions to others is associated with a complex brain activity involving the right medial prefrontal cortex when a nonverbal task is used.

Castelli et al., 2000 [22]	The regions responsible for processing information about intentions and the ability to make inferences about the mental states of others may have evolved from the ability to make inferences about the actions of other creatures.

Pierce et al., 2001 [23]	Compared to typical individuals, autistic "see" faces using different neural systems, unique to each individual.

Scholz et al., 2009 [24]	There are neighboring but distinct regions in the right temporo-parietal junction involved in ToM and orientation of attention.

Johnson et al., 2007 [25]	There is involvement of frontal and parietal attentional networks and sub-cortical excitatory systems in ADHD and a prefrontal cortex dysfunction in children with HFA.

Kana et al., 2007 [26]	The neural circuit linked to inhibition in individuals with ASD is atypically activated and is less synchronized, leaving inhibition to be accomplished by strategic control rather than automatically.

Schultz et al., 2000 [27]	Individuals with ASD demonstrate during facial discrimination, a pattern of brain activity consistent with strategies based on characteristics or traits more typical of the perception of non-facial objects.

Dapretto et al., 2006 [28]	A dysfunctional mirror neuron system may underlie the social deficits of autism.

Jones et al., 2008 [29]	The behavior of eye contact is already noticeably compromised in children two years of age with ASD, accompanying the person with autism for life.

Contributions

Highlights the importance of understanding biological markers, patterns of cortical organization and connectivity in advancing the treatment of AUT.

Highlights the role of the amygdala in the symptoms of ASD.

Relates the difficulties in understanding socially relevant movements in AUT to information processing in the visual cortex.

Presents data that validate hypothesis of abnormal brain activation in patients with impaired mentalizing.

Suggests evolutionary history for the abilities that make ToM.

Experiential factors play an important role in the development of the fusiform facial area, related to the processing faces.

Identifies difficulties in the investigation of brain functions that occupy regions close to each other or overlapping.

Provides detailed evidence of dysfunction in sustained attention in ADHD significantly higher than in HFA.

Identifies dysfunction in inhibitory cortical level, being disorganized and desynchronized.

Highlights possible dysfunction in processing stimuli related to biological and inanimate objects in ASD.

Substantiates hypothesis of the importance of mirror neurons in the development of social functions.

Subsidizes and highlights the importance of early diagnosis of ASD.


Manufacturer	Diameter (mm)	Mean Life	St. Dev

	.0	736	02

S&N – Trigen	5.0	436248	487507


Study	Parameter estimate	Standard error	Weight in fixed effects model	Weight in random effects model

ACT	−0.01220	0.01223	0.03788	0.11078

LRC	0.01437	0.01063	0.05015	0.11780

DASH	−0.01362	0.02348	0.01028	0.06695


Outcome	Per 10 μg/m3 PM2.5 exposure	Per 10 ppb NO2 exposure

mmHg (95% CI)	p-Value	mmHg (95% CI)	p-Value

Systolic blood pressure

Model 1	0.8 (0.3, 1.3)	0.002	–0.4 (–0.6, –0.1)	0.003

Model 2	0.9 (0.4, 1.4)	< 0.001	0.2 (–0.1, 0.4)	0.17


Data collection	Measurement tool	Data collected method	Timeframe

Measurement of total ulcer area	Centimetres squared;	Research assistant	Weekly: Post-treatment until healed or at 6 months

Tracing from photographs and counting squares

Measurement of ulcer depth	Centimetres;	Treating podiatrist	Weekly: post-treatment until healed or at 6 months

Using sterile probe

Ulcer pain	Visual analogue pain scale 100 mm	Treating podiatrist	Weekly: Pre-treatment, during treatment, post-treatment until healed or 6 months

Quality of life	EQ-5D-5 L tool	Participant questionnaire	Initial treatment, at 3 months, at 6 months

Direct health costs

Consumable costs for treatments	In dollars for each treatment	Treating podiatrist	Weekly, per participant until healed or at 6 months

Medicare Benefit Scheme (MBS)	MBS Care database, in dollars	Extraction from MBS database	End of project for each participant from initial to final treatment

Pharmaceutical Benefit Scheme (PBS)	PBS Care database, in dollars	Extraction from PBS database	End of project for each participant from initial to final treatment

Inpatient data	Monash Health:	Hospitalisation costs	Monash Health:

Admission duration, reason for admission, imaging and interventions, obtained from the patient record and from the Victorian Admitted Episodes Database	End of project

External organisation: End of project

External organisation: Admission duration, reason for admission, costs of any surgery for diabetes-related foot ulcers will be estimated using WEISS funding

Hospital based services (outpatient data)	Hours – time spent	Treating podiatrist	Weekly per participant until healed or at 6 months

Medical imaging and pathology for outpatients	Dollars – hospital based costs	Treating podiatrist	Monthly per participant until healed or at 6 months

Community based services	Number and cost of appointments	Participant interview	Monthly until healed or at 6 months

Private health appointments	Number and cost of appointments, eligibility for private health subsidies	Participant interview	Monthly until healed or at 6 months

Royal District Nursing Service for ulcer management	Frequency and cost of service	Participant interview	Monthly until healed or at 6 months

Ongoing ulcer care products	Valued using market prices	Participant interview	Monthly until healed or at 6 months

Parking costs for appointments	Dollars	Participant interview	Monthly until healed or at 6 months

Transportation costs to travel to appointments	Estimated through Australian Tax Office car rate cents per km	Participant interview	Monthly until healed or at 6 months

Productivity costs

Time taken from work for participant and/or any family member	Salary and hours taken from work	Participant/family interview	Monthly until healed or at 6 months


6MWD (m)	Overall	GROC < 2	GROC ≥ 2	P value

Pre-intervention

Mean (SD)	294.7 (78.4)	269.2 (93.9)	297.0 (77.3)	0.41

Post-intervention


Explanatory variable	d.f.	Mean square	F-value	P

TREATMENT	2	0.4168	5.08	0.0302

LARVAE	1	0.2237	3.44	0.0670

TREATMENT (DAY)	9	0.0831	1.28	0.2603

Error	92	0.0651


Variable (units)	Men	Women	P value

N	141	16	-

Age (y)	41.9 ± 9.7	42.0 ± 6.1	0.98

Body mass (kg)	75.0 ± 9.2	56.6 ± 7.1	<0.01

Body surface area (m2)	1.9 ± 0.1	1.6 ± 0.1	<0.01

Height (m)	176 ± 7	161 ± 5	<0.01

Body mass index (kg · m−2)	24.1 ± 2.2	20.9 ± 1.2	<0.01

Best race time (min)	217 ± 34	240 ± 32	0.03

Running experience (yr)	10.7 ± 9.8	9.5 ± 5.9	0.67

Completed marathons (number)	7 ± 3	5 ± 2	0.42

Average training distance · week−1 (km)	62.7 ± 27.8	59.5 ± 26.6	0.69

Training sessions of running · week−1 (number)	4.3 ± 1.0	4.4 ± 1.0	0.68


Murine models of infection	Immune outcome	Reference

FrCasE virus (MLV)	Enhanced memory cellular CD8+ responses	43

Influenza	Prolonged Ag presentation by DC; enhanced proliferation of CD8+ T cells	64

RSV	Modification of CD4+/CD8+ T-cell balance	65

LCMV	Innate immune activation;induction of virus-specific CD8+ T-cell response	66

Murine models of infection	Immune outcome

FrCasE virus (MLV)	Enhanced memory cellular CD8+ responses

Influenza	Prolonged Ag presentation by DC; enhanced proliferation of CD8+ T cells

RSV	Modification of CD4+/CD8+ T-cell balance

LCMV	Innate immune activation;induction of virus-specific CD8+ T-cell response


	Fungi	Bacteria

	Endorhiza	Rhizosphere	Endorhiza	Rhizosphere

	P	D	P	D	P	D	P	D


Sample	Residual level, mg/kg	μg/product

2,6-TDI	IPDI-1	IPDI-2	2,4-TDI	PI	CHI	4,4′-MDI	H12MDI	Total	Total

Glove 1	0.013	ND	ND	ND	ND	ND	0.064	ND	0.077	0.40

Glove 2	ND	ND	0.011	ND	ND	ND	3.0	0.022	3.0	18.7

Pastry bag	0.029	ND	ND	0.004	ND	ND	0.014	ND	0.047	7.4

	2,6-TDA	IPDA		2,4-TDA	ANL	CHA	4,4′-MDA	H12MDA	Total	Total

Glove 1	ND	ND		ND	1.0	ND	29	ND	30	106

Glove 2	ND	ND		ND	0.73	0.43	0.92	3.5	5.6	35

Pastry bag	ND	ND		ND	ND	ND	ND	ND	ND	ND

Sample

Glove 1

Glove 2

Pastry bag

Glove 1

Glove 2

Pastry bag

Residual level, mg/kg	μg/product

2,6-TDI	IPDI-1	IPDI-2	2,4-TDI	PI	CHI	4,4′-MDI	H12MDI	Total	Total

0.013	ND	ND	ND	ND	ND	0.064	ND	0.077	0.40

ND	ND	0.011	ND	ND	ND	3.0	0.022	3.0	18.7

0.029	ND	ND	0.004	ND	ND	0.014	ND	0.047	7.4

2,6-TDA	IPDA		2,4-TDA	ANL	CHA	4,4′-MDA	H12MDA	Total	Total

ND	ND		ND	1.0	ND	29	ND	30	106

ND	ND		ND	0.73	0.43	0.92	3.5	5.6	35

ND	ND		ND	ND	ND	ND	ND	ND	ND


Number of conditions	OR	95% CI	p-value

No chronic health condition	REFERENCE

Arthritis only	1.64	1.13 – 2.38	0.0099

Arthritis and one other condition	2.95	1.82 – 4.80	<.0001

Arthritis and two other conditions	2.80	1.50 – 5.26	0.0013

Arthritis and three or more other conditions	8.68	5.24 – 14.38	<.0001

Number of conditions	OR	95% CI	p-value

No chronic health cond	REFER

ition	ENCE

Arthritis only	1.64	1.13 – 2.38	0.0099

Arthritis and one other condition	2.95	1.82 – 4.80	<.0001

Arthritis and two other conditions	2.80	1.50 – 5.26	0.0013

Arthritis and three or more other conditions	8.68	5.24 – 14.38	<.0001


Parameter	Value

Highest heart rate	119 ± 25 beats/minute

Highest respiratory rate	31.7 ± 8.9 breaths/minute

Mean APACHE II score	19.8 ± 7.8

Mean SAPS II score	40.2 ± 16.1

Mean white cell count	13.2 ± 10.1 × 109/l

Mean haemoglobin	12.4 ± 2.2 g/dl (lowest value: 7.8 g/dl)

Mean platelet count	217 ± 218 × 109/l

Mean [urea]	13.6 ± 7.6 mmol/l

Mean [creatinine]	222 ± 218 μmol/l

Parameter

Highest heart rate

Highest respiratory rate

Mean APACHE II score

Mean SAPS II score

Mean white cell count

Mean haemoglobin

Mean platelet count

Mean [urea]

Mean [creatinine]


	Within-group difference	Between-group difference	Between-group P-value

	Acu-TENS	Placebo-TENS

Heart rate (beat min−1)	−4.50 (0.49)	0.79 (0.21)	−5.29 (0.37)	 .000

SBP (mmHg)	−4.95 (0.89)	0.35 (1.14)	−5.30 (0.85)	 .206

Rate pressure product	−940.9 (123.9)	140.9 (123.6)	−1081.0 (115.2)	 .010

	Within-group difference	Between-group difference	Between-group P-value

	Acu-TENS	Placebo-TENS

SBP (mmHg)	−4.95 (0.89)	0.35 (1.14)	−5.30 (0.85)	.206

Rate pressure product	−940.9 (123.9)	140.9 (123.6)	−1081.0 (115.2)	.010


Item	Home care group (n = 69)	Hospital care group (n = 69)	P	Standardized difference

Gender (n, male/female)	35/34	36/33	0.87	0.03

Age (yr, mean ± SD)	70.7 ± 13.9	70.7 ± 10.8	0.99	0.002

Primary site (n)			1.00

Lung	11	13		0.08

Stomach/esophagus	22	23		0.03

Liver/biliary tract/pancreas	17	15		0.07

Large intestine	9	8		0.04

Breast	2	2		0

Others	8	8		0

Performance status (n)			0.99

0	0	0		(incalculable)

1	12	12		0

2	22	20		0.06

3	27	28		0.03

4	8	9		0.04

Use anti-cancer agents (n, used/unused)a	1/68	2/67	1.00	0.10

Item	Home care group (n = 69)	Hospital care group (n = 69)	P

Gender (n, male/female)	35/34	36/33	0.87

Age (yr, mean ± SD)	70.7 ± 13.9	70.7 ± 10.8	0.99

Primary site (n)			1.00

Lung	11	13

Stomach/esophagus	22	23

Liver/biliary tract/pancreas	17	15

Large intestine	9	8

Breast	2	2

Others	8	8

Performance status (n)			0.99

0	0	0

1	12	12

2	22	20

3	27	28

4	8	9

Use anti-cancer agents (n, used/unused)a	1/68	2/67	1.00


	Beta coefficient	SE	t	p-value

Occupation	0.558	0.187	2.98	0.003

Length of VMW career	0.007	0.003	2.28	0.023

Reason for becoming VMW	-0.649	0.089	-7.33	<0.001

Knowledge of malaria transmission	0.989	0.136	7.30	<0.001

Knowledge of vector species	0.307	0.151	2.04	0.042

Knowledge of vector breeding places	0.574	0.139	4.13	<0.001

	Beta coefficient	SE

Occupation	0.558	0.187

Length of VMW career	0.007	0.003

Reason for becoming VMW	-0.649	0.089

Knowledge of malaria transmission	0.989	0.136

Knowledge of vector species	0.307	0.151

Knowledge of vector breeding places	0.574	0.139


Parameters	Symbol	Value

Duty factor	β	1/2, 4/5, 5/6

Turning radius	Rturning	600 mm, 800 mm, 1000 mm

Straight radius	RStraight	Inf

Running time	T	30 s

The moment of straight to turning	TS-T	10 s

The moment of turning to straight	TT-S	20 s

Gait period	Tperiod	1 s


Variable	Baseline	Three months	P value

ESR (mean ± SD, mm in the first hour)	25.4 ± 22.4	12.8 ± 18.5	0.038

CRP (mean ± SD, mg/L)	17.6 ± 18.4	10.8 ± 15.9	0.058

Prednisone use, n (%)	7 (44)	7 (44)	1.0

Prednisone dose (mean ± SD, mg/day)	2.0 ± 2.5	2.8 ± 5.2	0.24


Article	Method	MCInc/MCIc	Scans	ACC (%)	SEN (%)	SPE (%)	AUC

Cui et al., 2011	Multivariate predictors (MRI, CSF, and NM scores)	87/56	baseline	67.1	96.4	48.3	0.796

Ye et al., 2012	SLR+SS (MRI, genetic, and cognitive measures)	177/142	baseline	–	–	–	0.859

Eskildsen et al., 2013	Patterns of cortical thinning	134/122	6 months	75.8	75.4	76.1	0.809

		134/123	12 months	72.9	75.8	70.2	0.762

Raamana et al., 2015	Thickness network fusion	130/56	baseline	64.0	65.0	64.0	0.680

Proposed	Combination of MRI and thickness network	83/76	baseline	66.0	55.3	75.9	0.735

		83/61	6 months	76.4	65.6	84.3	0.813

		83/63	12 months	74.7	65.1	81.9	0.785

		83/42	18 months	73.9	70.5	77.1	0.773


Performance measures	Base case	Case 1	Case 2	Case 3	Case 4

Examination quantity	Total	326.9	321.3	324.6	324.0	324.0

Emergency patients	132.6	134.1	133.2	132.7	132.0

Outpatients	127.4	122.3	126.2	125.4	125.0

Inpatients	66.8	64.9	65.1	65.9	67.0

Wait time (min)	Total	53.9	29.3	30.4	31.1	30.1

Performance measures	Base case	Case 1	Case 2	Case 3	Case 4

Wait time (min)	Emergency patients	1.8	2.0	1.9	2.0	1.9

Outpatients	96.6	53.6	54.7	56.6	54.8

Inpatients	78.0	43.0	44.5	45.8	44.2

Equipment utilization		99.3%	97.9%	98.8%	98.5%	98.7%


	kappa

presence of activity periods	0.905*

presence of rhythmical activity	0.786*

	ICC (95% CI)

amount of activity periods	0.967 (0.951–0.978)*

dominant frequency	0.739 (0.624–0.822)*

second prevalent frequency	0.787 (0.672–0.864)*

third prevalent frequency	0.789 (0.672–0.867)*

minimal frequency	0.351 (0.149–0.525)#

maximal frequency	0.831 (0.750–0.887)*

highest value of acceleration peaks	0.841 (0.768–0.893)*

presence of activity periods

presence of rhythmical activity

amount of activity periods

dominant frequency

second prevalent frequency

third prevalent frequency

minimal frequency

maximal frequency

highest value of acceleration peaks


Theory	Favourable impact of coach change on team performance	Slope of the favourable impact over time

Vicious-circle theory	NO

Ritual scapegoating theory	NO

Common-sense theory	YES	=

Current study	YES	> in the short term and= in the long term

Theory	Favourable impact of coach change on team performance

Vicious-circle theory	NO

Ritual scapegoating theory	NO

Common-sense theory	YES

Current study	YES

Slope of the favourable impact over time

=

> in the short term and= in the long term


Normal versus tumor biomarkers	LN negative versus LN positive biomarkers

SLC39A5, C3orf32, TP73, CD1B, PCDHGA4, PCDHGA11, PCDHGA9, PCDHGA1, PCDHGB1, PCDHGB6, PCDHGA12, PCDHGB3, PCDHGB7, PCDHGA6, PCDHGA8, PCDHGA10, PCDHGA5, PCDHGB4, PCDHGA3, PCDHGA2, PCDHGB2, PCDHGA7, PCDHGB5, C20orf197, SLC16A5, FUT8, SLC15A2, C17orf93, PRAC, OCLN, TMEM144, FGF2, PDX1, CCL1, LILRB5, LCE3D, GPR45, LPO, CGB5	LAT2, TTC13, ARV1, NMT1, DCAKD, GJA1, OR7A17, LOX, KRT19, ZNF655, KRTAP4-4, TAAR5, SEMA3E, HOXD1


Phytoestrogen	Corr CC	p-Value	Corr CC	p-Value

Habitual (μg/Day) vs. Urine (μg/g Creatinine)	Recent (μg/Day) vs. Urine (μg/g Creatinine)

Naringenin	0.069	0.571	0.620	0.000

Luteolin	−0.104	0.398	−0.200	0.090

Kaempferol	−0.084	0.496	0.040	0.690

Quercetin	0.154	0.212	0.027	0.820

Total Flavonoids	0.055	0.653	0.240	0.043

Coumestrol	−0.035	0.800	0.120	0.320

Resveratrol	0.337	0.005	0.005	0.960

Total Phytoestrogens	0.730	0.000	0.410	0.0007


Viruses detected	Patients with acute diarrhea (N = 145) (%)

Norovirus GII	59 (40.7)

Norovirus GI	17 (11.7)

Astrovirus	5 (3.5)

Rotavirus	2 (1.4)

Adenovirus 40/41	0 (0.0)

Coinfections	11 (8.0)

Norovirus GI + GII	5 (3.5)

Norovirus GI + Rotavirus A	1 (0.7)

Norovirus GI + Astrovirus	1 (0.7)

Norovirus GII + Astrovirus	4 (2.8)

At least one virus detected	94 (64.8)

No virus detected	51 (35.2)


 	Lab #1 (Sequencing)	Lab #2 (Sequencing)	Lab #3 (Sequencing)	Lab #4 (Primer Extension)	Lab #5 (Real Time PCR)

Specimen Requirements	Preferred sample type*:Slides from FFPE block 1H&E stained slide sections with tumor circled; 4 matching unstained slides,10 microns each.	Preferred sample type: Archival FFPE or frozen surgical biopsies confirmed to contain >50% tumor by a surgical pathologist.1 H&E slide; 5 unstained sections,10 microns each.	Preferred sample type: FFPE tissue 6 unstained sections,10 microns each.	Preferred sample type: Pre-cut slides from FFPE. Send all slides within 5–7 days of cutting. Air dry. Do not oven dry. Store specimen at room temperature (20–23.5°C). 5 unstained sections, 7 microns each	Preferred sample type: FFPE block, unstained slides, or fresh snap frozen biopsy 5 unstained sections, 7 microns each

Genotyping	Method: PCR amplification followed by Direct Sanger sequencing (Big Dye v. 1.1)Detected mutations: KRAS codons 12 and 13	Method: PCR amplification followed by standard bidirectional sequencing on ABI 3100. Detected mutations: KRAS codons 12 and 13	Method: PCR amplification followed by sequencing.Detected mutations: KRAS codons 12,13 and 61	Method: Single nucleotide primer extension with fragment analysis by capillary electrophoresis using a modified SNaPshot assay. Detected mutations: KRAS codons 12 and 13	Methods are propietary: qualitative real time PCR Detected mutations: KRAS codons 12 and 13

Lower Limit of Detection	20% when ≥ 40% tumor cells present	20%	15-20%	10% when ≥ 2% tumor cells present	1-5%

	Lab #1 (Sequencing)	Lab #2 (Sequencing)	Lab #3 (Sequencing)	Lab #4 (Primer Extension)

Specimen Requirements	Preferred sample type*:Slides from FFPE block 1H&E stained slide sections with tumor circled; 4 matching unstained slides,10 microns each.	Preferred sample type: Archival FFPE or frozen surgical biopsies confirmed to contain >50% tumor by a surgical pathologist.1 H&E slide; 5 unstained sections,10 microns each.	Preferred sample type: FFPE tissue 6 unstained sections,10 microns each.	Preferred sample type: Pre-cut slides from FFPE. Send all slides within 5–7 days of cutting. Air dry. Do not oven dry. Store specimen at room temperature (20–23.5°C). 5 unstained sections, 7 microns each

Genotyping	Method: PCR amplification followed by Direct Sanger sequencing (Big Dye v. 1.1)Detected mutations: KRAS codons 12 and 13	Method: PCR amplification followed by standard bidirectional sequencing on ABI 3100. Detected mutations: KRAS codons 12 and 13	Method: PCR amplification followed by sequencing.Detected mutations: KRAS codons 12,13 and 61	Method: Single nucleotide primer extension with fragment analysis by capillary electrophoresis using a modified SNaPshot assay. Detected mutations: KRAS codons 12 and 13

Lower Limit of Detection	20% when ≥ 40% tumor cells present	20%	15-20%	10% when ≥ 2% tumor cells present

Lab #5 (Real Time PCR)

Preferred sample type: FFPE block, unstained slides, or fresh snap frozen biopsy 5 unstained sections, 7 microns each

Methods are propietary: qualitative real time PCR Detected mutations: KRAS codons 12 and 13

1-5%


Behavior	HIV positives

Had sex past year	71.3

Had steady partner past year	50.3

Used condoms with steady partner past month

Never	47.7

Seldom	23.9

Often	13.6

Always	14.8

Had sex with casual female partner past year	35.4

Used condoms with casual female partners past month

Never	42.3

Seldom	22.5

Often	13.5

Always	21.6

Sold sex last year	2.7

Purchased sex last year	20.0

Condom use with FSW last month

Never	45.2

Seldom	20.2

Often	6.7

Always	27.9

Gave used needle to other IDU last week	21.1


	CspA	CspZ	ErpPa	ErpCa	ErpAa	p43	BBK32	BGA66	BGA71	CD59-like protein

Synonyms and other designations	CRASP-1	CRASP-2	CRASP-3	CRASP-4	CRASP-5	–	–	–	–	–

BbCRASP-1	BbCRASP-2	BbCRASP-3 BBN38	BbCRASP-4	BbCRASP-5

BBA68	BBH06			ErpI

ZS7.A68				ErpN

FHBP				BBP38

BBL39

OspE

Gene name	cspA	cspZ	erpP	erpC	erpA	ND	bbk32	bga66	bga71	ND

Origin	Bb, Ba, Bs	Bb	Bb	Bb	Bb	Bb	Bb	Bba	Bba	Bb

Confers serum resistance	Yes	Yes	No	No	No	ND	Yes	Yes	Yes	ND

Interaction with complement regulators/components	FH	FH	FHR-1	FHR-1	FHR-1	C4Bp	C1r	C7, C8, C9, TCC	C7, C8, C9, TCC	TCC

FHL-1	FHL-1	FHR-2	FHR-2	FHR-2

C7, C8, C9, TCC		FHR-5		FHR-5

Interaction with plasmin(ogen)	Yes	Yes	Yes	Yes	Yes	ND	ND	ND	ND	ND

Affected complement pathways	AP, TP	AP	–	–	–	CP/LP(?)	CP	TP	TP	TP


	Danish early-vaccination era data set	Global post-vaccination era data set

Length of sequences	800	800

Number of sequences	18	40

Average number of differences	12.2	31.0

# synonymous substitutions	26	131

# non-synonymous substitutions	32	71

Average Pi (nucleotide diversity)

1. all sites	0.014	0.040

2. synonymous sites	0.030	0.109

3. non-synonymous sites	0.009	0.019

Transition/transversion bias	2.2	9.4

Codon usage bias (ENC)	53	55

	Danish early-vaccination era data set	Global post-vaccination era data set

Average number of differences	12.2	31.0

# synonymous substitutions	26	131

# non-synonymous substitutions	32	71

Average Pi (nucleotide diversity)

1. all sites	0.014	0.040

2. synonymous sites	0.030	0.109

3. non-synonymous sites	0.009	0.019

Transition/transversion bias	2.2	9.4

Codon usage bias (ENC)	53	55


Characteristics	Number (%)	Characteristics	Number (%)

Kebele	 	Religion

 Yikaho	63(15.1)	Orthodox Christian	337(80.6)

 Mahdid	62(14.8)	Muslims	81(19.4)

 Bambaho	126(30.1)	Educational level

 Dubaba	167(40)	Illiterate	248(59.3)

Gender	 	Primary (grades 1–8)	142(34.0)

 Male	262(62.7)	Secondary and above	28(6.7)

 Female	156(37.3)	Occupation

Age (years)	 	Farmer	349(83.5)

 18-24	67(16.0)	Others	69(16.5)

 25-49	303(72.5)	Family size

 50-64	35(8.4)	1-4	230(55.0)

 65+	13(3.1)	5+	188(45.0)

Ethnicity

 Amhara	293(70.1)

 Agew	63(15.1)

 Gumuz	62(14.8)

Marital status

 Unmarried	48(11.5)

 Married	365(85.2)

 Others	14(3.3)

Characteristics

Kebele

Yikaho

Mahdid

Bambaho

Dubaba

Gender

Male

Female

Age (years)

18-24

25-49

50-64

65+

Ethnicity

Amhara

Agew

Gumuz

Marital status

Unmarried

Married

Others


Protein	Gene	Hz vs WT (fold change)	P value	Hz + IGF-1 vs Hz (fold change)	P value

IGF-1R and Intracellular signaling

 Insulin-like growth factor 1 receptor	igf1r	1.44	0.0001	1.29	0.001

 Neuroblastoma ras oncogene	nras	1.53	0.0004	−1.08	0.001

 Jun oncogene	jun	−2.03	0.0006	1.05	0.01

 FBJ osteosarcoma oncogene	fos	−1.44	0.001	−1.16	0.13

Inflammation and apoptosis

 Chemokine (C-C motif) receptor 5	ccr5	4.38	0.0001	−4.87	0.0001

 Chemokine (C-C motif) ligand 6	ccl6	4.34	0.0002	−4.02	0.0001

 Colony stimulating factor 1 receptor	csf1r	2.49	0.0004	−2.41	0.0006

 Complement component 1, q subcomponent, α p	c1qa	5.40	0.0002	−3.43	0.0006

 Lysozyme 2	lyz2	2.99	0.0019	−2.31	0.004

 Lymphocyte antigen 96	ly96	1.71	0.003	−1.38	0.04

Interleukin 10 receptor beta	il10rb	1.75	0.004	−1.80	0.004

 Serum amyloid A 1	saa1	3.74	0.0004	−1.70	0.006

 Secreted phosphoprotein 1	spp1	2.44	0.001	−1.80	0.005

 Allograft inflammatory factor 1	aif1	1.95	0.0001	−2.82	0.00006

 Apoptotic peptidase activating factor 1	apaf	1.05	0.05	−1.05	0.05

Cytoskeleton

 Tubulin, beta 2A	tubb2a	−2.49	0.001	1.56	0.002

 Vinculin	vcl	−1.49	0.003	1.31	0.06

 MAP/microtubule affinity-regulating kinase 2	mark2	−1.52	0.01	1.34	0.05

 Actin, beta	actb	1.65	0.0006	−1.58	0.0001

 Serine/threonine kinase 11	stk11	−1.38	0.019	1.36	0.05

 Myosin IB	myo1b	1.43	0.05	−1.37	0.03

Intercellular junctions

 Claudin 1	cldn1	−1.04	0.21	−1.23	0.18

 Claudin 7	cldn7	1.48	0.003	−1.15	0.12

 Claudin 14	cldn14	2.37	0.0006	−1.78	0.0003

 Junction adhesion molecule 2	Jam2	1.23	0.03	−1.60	0.006

 Cadherin 5	cdh5	1.70	0.0006	−1.80	0.0001

 Desmocollin 2	dsc2	1.46	0.003	−1.46	0.001

Extracellular matrix

 Integrin beta 2	itgb2	−2.46	0.0006	2.03	0.0001

 Connective tissue growth factor	ctgf/bp8	−1.60	0.001	−1.57	0.006

 Proteoglycan 4	prg4	2.21	0.006	−2.24	0.0001

 Collagen, type I, alpha 2	col1a2	−1.58	0.001	1.13	0.02

 Collagen, type III, alpha 1	col3a1	−1.71	0.0003	1.08	0.38

 Collagen, type V, alpha 2	col5a2	1.66	0.0001	−3.99	0.0006

 Fibronectin 1	fn1	1.50	0.005	−1.45	0.003


Animal	Model	Preconditioning time/approach	TLR/ischemia	Result and mechanism	Author	Reference

Mice	MCAO, 60-min ischemia, 24-h reperfusion	72 h/12-min ischemia	Ischemic preconditioning	Decrease brain infarction volume, and IRF gene participate in brain protection	Stevens SL	[79]

Mice	MCAO, 60-min ischemia, 6-h reperfusion	24 h/IP	TLR2, Pam3CSK4	Decrease brain infarction and edema, improve neurological function, and maintain BBB function	Hua F	[60]

Mice	MCAO, 45-min ischemia, 24-h reperfusion	72 h/subcutaneous injection	TLR3, poly-ICLC	Decrease brain infarction volume and improve neurological function	Packard AEB	[63]

Mice	MCAO, 120-min ischemia, 22-h reperfusion	24 h/systemic injection	TLR3 poly-IC	Decrease brain infarction volume and neurological defect and lower the levels of TNF-α and IL-6 in cortex and striatum	Pan LN	[66]

Mice	MCAO, 60-min ischemia, 24-h reperfusion	1 h/IP	TLR3 poly-IC	Decrease brain infarction and prevention of Fas/FADD interaction	Zhang X	[67]

Spontaneously hypertension rats	MCAO, 120-min ischemia, 22-h reperfusion	2, 3, 4 days/IV	TLR4 LPS	Decrease brain infarction volume, mediated by TNF-α	Tasaki K	[72]

Mice	MCAO, 120-min ischemia, 47-h reperfusion	48 h/IP	TLR4 LPS	Decrease brain infarction volume, inhibit the infiltration of neutrophil and activation of the microglia	Rosenzweig HL	[73]

Mice	MCAO, 40-, 45-, 60-min ischemia, 24-h reperfusion	72 h/IP	TLR4 LPS	Decrease brain infarction volume that was mediated by IRF3	Marsh B	[61]

Mice	MCAO, 40-to 60-min ischemia, 24-h reperfusion	72 h/subcutaneous injection	TLR4 LPS	Decrease brain infarction volume, and TRIF-IRF3 play vital role	Vartanian KB	[58]

Mice	MCAO, 60-min ischemia, 24-h reperfusion	72 h/IP	TLR4	Decrease brain infarction volume, and inhibit TNF-α signaling pathway after cerebral ischemia	Rosenzweig HL	[76]

Mice	MCAO, 45-to 60-min ischemia, 23-h reperfusion	72 h/subcutaneous injection	TLR7 GDQ	Decrease brain infarction volume and neurological functional score that was protected through I type interferon	Leung PY	[62]

Mice	MCAO, 60-min ischemia, 72-h reperfusion	30 min/IV	TLR8 R848	Increase neurological function defect and mortality, activate pro-apoptotic JNK pathway and inflammation	Tang SC	[56]

Mice	MCAO, 60-min ischemia, 24-h reperfusion	72 h/IP	TLR9 CpG-ODN	Decrease brain infarction volume and TNF-α play a vital role	Stevens SL	[64]

Mice	MCAO, 60-min ischemia, 24-h reperfusion	72 h/IP or subcutaneous injection	TLR9 CpG-ODN	Decrease brain infarction volume and IRF gene participate in cerebral protection after ischemia	Stevens SL	[79]

Mice	MCAO, 60-min ischemia, 24-h reperfusion	1 h/IP	TLR9 CpG-ODN	Decrease brain infarction and activation of PI3K/Akt signaling	Lu C	[78]

Animal	Model	Preconditioning time/approach	TLR/ischemia	Result and mechanism	Author	Reference

Mice	MCAO, 60-min ischemia, 24-h reperfusion	1 h/IP	TLR3 poly-IC	Decrease brain infarction and prevention of Fas/FADD interaction	Zhang X	[67]

Spontaneously hypertension rats	MCAO, 120-min ischemia, 22-h reperfusion	2, 3, 4 days/IV	TLR4 LPS	Decrease brain infarction volume, mediated by TNF-α	Tasaki K	[72]

Mice	MCAO, 120-min ischemia, 47-h reperfusion	48 h/IP	TLR4 LPS	Decrease brain infarction volume, inhibit the infiltration of neutrophil and activation of the microglia	Rosenzweig HL	[73]

Mice	MCAO, 40-, 45-, 60-min ischemia, 24-h reperfusion	72 h/IP	TLR4 LPS	Decrease brain infarction volume that was mediated by IRF3	Marsh B	[61]

Mice	MCAO, 40-to 60-min ischemia, 24-h reperfusion	72 h/subcutaneous injection	TLR4 LPS	Decrease brain infarction volume, and TRIF-IRF3 play vital role	Vartanian KB	[58]

Mice	MCAO, 60-min ischemia, 24-h reperfusion	72 h/IP	TLR4	Decrease brain infarction volume, and inhibit TNF-α signaling pathway after cerebral ischemia	Rosenzweig HL	[76]

Mice	MCAO, 45-to 60-min ischemia, 23-h reperfusion	72 h/subcutaneous injection	TLR7 GDQ	Decrease brain infarction volume and neurological functional score that was protected through I type interferon	Leung PY	[62]

Mice	MCAO, 60-min ischemia, 72-h reperfusion	30 min/IV	TLR8 R848	Increase neurological function defect and mortality, activate pro-apoptotic JNK pathway and inflammation	Tang SC	[56]

Mice	MCAO, 60-min ischemia, 24-h reperfusion	72 h/IP	TLR9 CpG-ODN	Decrease brain infarction volume and TNF-α play a vital role	Stevens SL	[64]

Mice	MCAO, 60-min ischemia, 24-h reperfusion	72 h/IP or subcutaneous injection	TLR9 CpG-ODN	Decrease brain infarction volume and IRF gene participate in cerebral protection after ischemia	Stevens SL	[79]

Mice	MCAO, 60-min ischemia, 24-h reperfusion	1 h/IP	TLR9 CpG-ODN	Decrease brain infarction and activation of PI3K/Akt signaling	Lu C	[78]


Variable	Category	A/A	G/A	Total	P value

Surfactant	Yes	26 (92.9%)	2 (7.1%)	28 (100%)	0.271


Sl. number	Age	Gender	Site	Size	Histopathological category

Case1	40	Female	Gingiva	1-2 cm	Cellular phase

Case2	40	Female	Buccal mucosa	1-2 cm	Capillary phase, LCH type

Case3	09	Male	Buccal mucosa	<1 cm	Capillary phase, non-LCH type

Case4	23	Female	Gingiva	1-2 cm	Involutionary phase

Sl. number	Age	Gender	Site	Size	Histopathological category

Case4	23	Female	Gingiva	1-2 cm	Involutionary phase


Population	Region of interest	Emax, %	EC50, ng/mL

AD	Frontal cortex	81.1 (CV%: 3.2)	1.06 (CV%: 19.6)


Factors	Moxi	(%)	Non-Moxi	(%)

Number	276	 	1992

Age	44.78	 	38.5

Sex (male)	150	(54.3)	1129	(56.7)

Site of disease

Pulmonary	165	59.8	1182	59.3

Meningeal	12	4.3	9	0.5

Central Nervous System	2	0.7	4	0.2

Ocular	10	3.6	12	0.6

Other extra-pulmonary	87	31.5	786	39.4

Country of origin

Australian	22	8.0	219	11.0

Overseas	254	92.0	1773	89.0

HIV status

Positive	5	1.8	32	1.6

Negative	67	24.3	328	16.5

Unknown	204	73.9	1632	81.9

Diagnosis method

Culture	217	78.6	1521	76.3

Histological	13	4.7	161	8.1

PCR/NAT	19	6.9	116	5.8

Radiological	9	3.3	126	6.3

Clinical	17	6.2	58	2.9

Microscopic Examination	1	0.4	10	0.5

Sensitivities - Of culture positive cases

Fully sensitive	148	68.2	1410	92.6

MDRTB	39	18.0	0	0.0

XDRTB	2	0.9	0	0.0

Other resistance patterns	26	12.0	103	6.8

 Isoniazid Resistance	24	92.3	97	94.2

 Rifampicin resistance	1	3.8	0	0.0

 Pyrazinamide resistance	1	3.8	2	1.9

 Ethambutol resistance	0	0.0	3	2.9

 Other agents	0	0.0	1	1.0

Sensitivity results pending	2	0.9	9	0.6

Factors	Moxi	(%)	Non-Moxi	(%)

Overseas	254	92.0	1773	89.0

HIV status

Positive	5	1.8	32	1.6

Negative	67	24.3	328	16.5

Unknown	204	73.9	1632	81.9

Diagnosis method

Culture	217	78.6	1521	76.3

Histological	13	4.7	161	8.1

PCR/NAT	19	6.9	116	5.8

Radiological	9	3.3	126	6.3

Clinical	17	6.2	58	2.9

Microscopic Examination	1	0.4	10	0.5

Sensitivities - Of culture positive cases

Fully sensitive	148	68.2	1410	92.6

MDRTB	39	18.0	0	0.0

XDRTB	2	0.9	0	0.0

Other resistance patterns	26	12.0	103	6.8

Isoniazid Resistance	24	92.3	97	94.2

Rifampicin resistance	1	3.8	0	0.0

Pyrazinamide resistance	1	3.8	2	1.9

Ethambutol resistance	0	0.0	3	2.9

Other agents	0	0.0	1	1.0

Sensitivity results pending	2	0.9	9	0.6


Sample	Spiked Level (mg/kg)	Recovery (%)	RSD a (%)

fresh tea leaf	0.01	92.3 ± 6.51	10.2

0.05	84.3 ± 5.84	10.4


FGD content analysis	Men – young FGD

Meaning unit	I think smoking is not related to sugar disease but there must be small part that can affect sugar disease; most smokers, including me, we usually deny

Condensed meaning unit	Smoking is related to diabetes ‘but small part’; smokers deny bad effect of smoking;

Codes	Smoking only partly related to diabetes

Smokers deny bad effect of smoking

Aware of healthy lifestyle but ignoring

Codes cluster	Diabetes content area:

-

Risk factors content area:

Smoking only partly related to diabetes

Smokers deny bad effect of smoking

Aware of healthy lifestyle but ignoring

Codes	Aware of healthy lifestyle but ignoring

Codes cluster	Diabetes content area:

-

Risk factors content area:

Smoking only partly related to diabetes

Smokers deny bad effect of smoking

Aware of healthy lifestyle but ignoring


Ligand	Mutagenicity	Carcinogenicity

	Salmonella typhimurium(CPDB)	Salmonella typhimurium(Kazius/Bursi)	Rodent(multiple sex)	Rat(both sex)	Mouse(both sex)

SAHA	no	no	no	no	yes

1a	no	no	no	no	no

1b	no	no	no	no	yes

1c	no	no	no	no	no

1d	no	no	no	no	no

1e	no	no	yes	no	no

1f	no	no	no	no	no

2a	no	no	no	no	yes

2b	no	no	no	no	yes

2c	no	no	no	no	yes

2d	no	no	no	no	yes

2e	no	no	no	no	yes

2f	no	no	no	no	yes

Ligand	Mutagenicity	Carcinogenicity

	Salmonella typhimurium(CPDB)	Salmonella typhimurium(Kazius/Bursi)	Rodent(multiple sex)	Rat(both sex)	Mouse(both sex)

1b	no	no	no	no	yes

1c	no	no	no	no	no

1d	no	no	no	no	no

1e	no	no	yes	no	no

1f	no	no	no	no	no

2a	no	no	no	no	yes

2b	no	no	no	no	yes

2c	no	no	no	no	yes

2d	no	no	no	no	yes

2e	no	no	no	no	yes

2f	no	no	no	no	yes


Variable	n(%) n = 105

Age (mean(SD))	63.4 (20.1)

Age category	-

20–49	24(23)

50–74	38(36)

75–84	25(24)

85+	18(17)

Female	67(64)

Secondary care antibiotic use	77(73)

Trimethoprim 1	63(82)

Co-amoxiclav 1	22(29)

Amoxicillin 1	66(86)

Nitrofurantoin 1	3(4)

Visited hospital in previous 12 months	53(50)

Antibiotic use in previous 12 months	-

Yes	21(20)

Unknown 2	79(75)

Co-morbidity	-

Asthma	14(13)

Diabetes mellitus	16(15)

COPD	3(3)

History of smoking	46(44)

ariable	%) n = 105

Age (mean(SD))	63.4 (20.1)

Age category	-

20–49	24(23)

50–74	38(36)

75–84	25(24)

85+	18(17)

Female	67(64)

Secondary care antibiotic use	77(73)

Trimethoprim 1	63(82)

Co-amoxiclav 1	22(29)

Amoxicillin 1	66(86)

Nitrofurantoin 1	3(4)

Visited hospital in previous 12 months	53(50)

Antibiotic use in previous 12 months	-

Yes	21(20)

Unknown 2	79(75)

Co-morbidity	-

Asthma	14(13)

Diabetes mellitus	16(15)

COPD	3(3)

History of smoking	46(44)


			msSNP	Location error by the composite likelihood approach

					Causal SNP out	Causal SNP in

SNP density (kb/SNP)	No. SNPs	No. regions	χ21	Location error	LD	kb	LD	kb


Epidemiological and demographic variable	Number of cases	Deaths	Case fatality rate	Incidence rate

n	%	n	%	/100,000

Region of probable infection site

North	95	3.5	40	42.1	0.34

Northeast	11	0.4	5	45.4	<0.01

Southeast	423	14.2	194	45.8	0.05

South	574	19.3	192	33.4	0.25

Midwest	472	15.9	184	38.9	0.90

Left blank or unknown	177	10.3	63	34.4	–

Infection zone

Urban	151	8.6	60	39.7	–

Rural	1261	72.0	460	36.5	–


	Univariate	Multivariatea

Group	OR (95 % CI)	P	OR (95 % CI)	P

Moderate to severe hypoatremia	1.91 (1.197–3.033)	0.007	3.61 (1.438–9.049)	0.006


	Effect	β	SE	P-Value

MVPA	Intercept	3.233	0.397	<0.001

	Maturity Offset	−0.077	0.098	0.434

	Maturity Offset* Maturity Offset	0.026	0.009	0.005

	Sex (ref = girl)	1.574	0.335	<0.001

	Family Support	0.677	0.128	<0.001

	Maturity Offset* Family Support	−0.080	0.028	0.004

	Family Support* Sex (ref = girl)	−0.298	0.118	0.012

	Friend Support	0.267	0.055	<0.001

	Mother’s Ed	0.355	0.192	0.065

MVPA-	Intercept	2.070	0.274	<0.001

PM Weekday	Maturity Offset	−0.251	0.050	<0.001

	Maturity Offset* Maturity Offset	0.026	0.009	0.004

	Sex (ref = girl)	0.385	0.126	0.002

	Family Support	0.315	0.065	<0.001

	Friend Support	0.352	0.056	<0.001

	Mother’s Ed	0.455	0.194	0.019

Effect	β	SE	P-Value

Intercept	3.233	0.397	<0.001

Maturity Offset	−0.077	0.098	0.434

Maturity Offset* Maturity Offset	0.026	0.009	0.005

Sex (ref = girl)	1.574	0.335	<0.001

Family Support	0.677	0.128	<0.001

Maturity Offset* Family Support	−0.080	0.028	0.004

Family Support* Sex (ref = girl)	−0.298	0.118	0.012

Friend Support	0.267	0.055	<0.001

Mother’s Ed	0.355	0.192	0.065

Intercept	2.070	0.274	<0.001

Maturity Offset	−0.251	0.050	<0.001

Maturity Offset* Maturity Offset	0.026	0.009	0.004

Sex (ref = girl)	0.385	0.126	0.002

Family Support	0.315	0.065	<0.001

Friend Support	0.352	0.056	<0.001

Mother’s Ed	0.455	0.194	0.019


Run (session)	Total Samples	Average Strokes per Minute (SPM)	Number of Observation slices	Type of run

A	6,500	33.4	13	inner-club competition

B	8,000	15.4	8	training

C	4,500	32.0	9	inner-club competition

D	5,000	31.2	10	inner-club competition

E	8,000	15.0	8	recovery

Run (session)	Total Samples	Average Strokes per Minute (SPM)	Number of Observation slices

A	6,500	33.4	13

B	8,000	15.4	8

C	4,500	32.0	9

D	5,000	31.2	10

E	8,000	15.0	8

Type of run

inner-club competition

training

inner-club competition

inner-club competition

recovery


DerSimonian and Laird results

Study

Cornelissen 2009

De Witte 1994

Fielding 2009

Goldstone 2008

Hunault 2004

Labar 2004

Ribera 2005

Sebban 1994

Takeuchi 2002

Ueda 1998

10 studies, I2 = 0.0, τ2 = 0.0.

DL pooled result [95% CI]: HR = 0.86 [0.77, 0.97]; z = −2.48; P–value = 0.013.

HKSJ pooled result [95% CI]: HR = 0.86 [0.77, 0.96]; t = −3.19; P–value = 0.011 (df = 9).


Characteristics	Mean (SD); n (%)	Range:

Age in years	77.7 (5.89)	66-90

Women	25 (45.5%)	N/A

At least 1 fall in last 12 months	14 (25%)	N/A

BMI	25.8 (4.4)	14-42

Years of education	12.1 (3.4)	(8-20)

Cognition

 MMSE Score (0-30)	26.8 (2.1)	21-30

 MoCA score	22.4 (3.2)	15-28

 Letter Number Sequencing (LNS)	7.6 (2.4)	3-13

 TMT A (seconds)	55.8 (20.9)	23-102

 TMT B (seconds)	178.8 (108.6)	55-539

 Digit Symbol Coding	41 (14.4)	19-71

Gait Velocity (m/s)

 Single Gait Velocity (sGV)	0.87 (0.2)	0.44-1.50

 Verbal Gait Velocity (vGV)	0.65 (0.2)	0.32-1.00

 Counting Gait Velocity (cGV)	0.63 (0.2)	0.34-1.06

Characteristics

Age in years

Women

At least 1 fall in last 12 months

BMI

Years of education

Cognition

MMSE Score (0-30)

MoCA score

Letter Number Sequencing (LNS)

TMT A (seconds)

TMT B (seconds)

Digit Symbol Coding

Gait Velocity (m/s)

Single Gait Velocity (sGV)

Verbal Gait Velocity (vGV)

Counting Gait Velocity (cGV)


RSSI location	SVD imaging biomarker	Frequency [i.e., number of patients (%)]	Median volume or score (IQR)	% [median (IQR)] of total ICV

Cerebellum/ brainstem	WMH	7/7 (100)	19.69 (16.66) ml	1.27 (1.19)

Cavitated WMH	1/7 (14)	0.49 ml	3.14 × 10−4

Lacunes	2/7 (28)	0.09 ml	0.61 × 10−4

Perivascular spaces	7/7 (100)	BG score: 2 (1)	Not applicable

CS score: 2 (2)

Microbleeds	1/7 (29)	1	Not applicable

Old cortical stroke lesions	2/7 (28)	0.61 ml	4.92 × 10−4


Name	Sel	Rec	VRec	VarN	M	MM	CEM	Seq	Tree	Ref

FPG	Yes	Yes	No	No	Yes	No	No	Yes	No	JH

EasyPop	No	Yes	No	No	Yes	Yes	No	No	Yes	B01

SimuPop	Yes	Yes	Yes	Yes	Yes	Yes	No	No	Yes	P05

FREEGENE	Yes	Yes	Yes	Yes	Yes	No	No	No	No	H07

GenomePop	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	C08


 	Educational levels

Junior high school	High school	Junior or career college	University or higher education	P for trend

Men

 Number of subjects	10 350	8437	1074	1968

 Age, years	50.5	48.1	47.5	46.7	<0.001

 Previous history of stroke, ischemic heart disease, or cancer, %	3.6	3.0	2.8	2.3	<0.001

 Current drinker, %	64.3	69.3	65.1	65.9	0.006

 Current smoker, %	54.9	53.1	51.0	47.0	<0.001

 High perceived mental stress, %	20.0	29.3	33.9	43.8	<0.001

 Living with spouse, %	76.0	86.4	87.9	90.6	<0.001

 Full-time worker, %	96.0	97.4	97.8	97.8	<0.001

Women

 Number of subjects	12 624	8894	2305	504

 Age, years	50.7	48.0	46.3	45.7	<0.001

 Previous history of stroke, ischemic heart disease, or cancer, %	4.1	3.3	3.9	3.1	0.08

 Current drinker, %	9.0	11.0	11.0	10.2	<0.001

 Current smoker, %	7.6	6.8	6.5	6.5	0.02

 High perceived mental stress, %	18.5	22.8	29.3	40.9	<0.001

 Living with spouse, %	69.6	81.6	81.6	83.2	<0.001

 Full-time worker, %	74.0	76.7	76.5	85.9	<0.001

	Educational levels

Junior high school	High school	Junior or career college

Men

Number of subjects	10 350	8437	1074

Age, years	50.5	48.1	47.5

Previous history of stroke, ischemic heart disease, or cancer, %	3.6	3.0	2.8

Current drinker, %	64.3	69.3	65.1

Current smoker, %	54.9	53.1	51.0

High perceived mental stress, %	20.0	29.3	33.9

Living with spouse, %	76.0	86.4	87.9

Full-time worker, %	96.0	97.4	97.8

Women

Number of subjects	12 624	8894	2305

Age, years	50.7	48.0	46.3

Previous history of stroke, ischemic heart disease, or cancer, %	4.1	3.3	3.9

Current drinker, %	9.0	11.0	11.0

Current smoker, %	7.6	6.8	6.5

High perceived mental stress, %	18.5	22.8	29.3

Living with spouse, %	69.6	81.6	81.6

Full-time worker, %	74.0	76.7	76.5


Participant characteristics	N (%)

Gender

 Men	1 (6)

 Women	16 (94)

Mean age (years)	38 (range 30–47)

Mean age of allergic children (years)	3 (range 0.5-10)

First health care contact

 Emergency Department	10 (59)

 Family Physician	4 (23)

 Other	3 (18)

Allergen associated with first reaction

 Tree nuts	6 (35)

 Peanuts	4 (24)

 Fish	2 (12)


IC50 (ng mL−1): median (values obtained with two independent experiments)

	Fraction Weight (%)	Distribution of PnTX-G (%)	KB cells (72 h of incubation)	Neuro2A cells (24 h of incubation)	Undifferentiated Caco-2 cells (48 h of incubation)

F1	4.9	0	1023 (958, 1088)	N.R. (45%)	N.R. (44.5%)

F2	50.3	0	0.21 (0.18, 0.24)	11 (5–17)	N.R. (41.6%)


Question	Percent of responses correct (2011–2012)	Percent of responses correct (2012–2013)	Percent of responses correct (2013–2014)

There is no cure for asthma	80.8	84.9	90.3

Although asthma causes breathing problems, asthma episodes are not dangerous	93.8	96.4	97.9

Taking medications every day can help prevent an asthma episode	–	87.9	86.5

A person should take steroids for asthma to grow muscle mass for better athletic ability	86.8	89.7	91.2

Inhaled steroids have the same side effects as steroids taken by mouth	55.0	68.5	66.8

Very little can be done to reduce environmental triggers of asthma	69.0	76.1	78.2

Asthma medications are not addictive	51.4	55.9	66.6

People with asthma should not participate in sports	97.2	96.4	98.2

Asthma episodes always occur suddenly, without warning	71.5	78.1	84.4

Asthma can be caused by emotional stress or other psychological problems	31.9	82.0	83.6

A rescue or reliever medication (albuterol) helps during an asthma episode by making you breathe faster	47.6	63.3	65.1

Question	Percent of responses correct (2011–2012)	Percent of responses correct (2012–2013)	Percent of responses correct (2013–2014)

A person should take steroids for asthma to grow muscle mass for better athletic ability	86.8	89.7	91.2

Inhaled steroids have the same side effects as steroids taken by mouth	55.0	68.5	66.8

Very little can be done to reduce environmental triggers of asthma	69.0	76.1	78.2

Asthma medications are not addictive	51.4	55.9	66.6

People with asthma should not participate in sports	97.2	96.4	98.2

Asthma episodes always occur suddenly, without warning	71.5	78.1	84.4

Asthma can be caused by emotional stress or other psychological problems	31.9	82.0	83.6

A rescue or reliever medication (albuterol) helps during an asthma episode by making you breathe faster	47.6	63.3	65.1


	No decrease in haemoglobin, n (%)	With a decrease in haemoglobin, n (%)

Celecoxib N = 872	841 (96.44)	31 (3.56)

Diclofenac N = 438	412 (94.06)	26 (5.94)

	OR = 1.71 (1.00–2.92)

	No decrease in haemoglobin, n (%)

Celecoxib N = 872	841 (96.44)

Diclofenac N = 438	412 (94.06)

	OR = 1.71 (1.00–2.92)


 	NTM lung diseases patients (N = 84)	Non-NTM BE patients (N = 47)	P value

Any isolates	17 	(20.2%)	12 	(25.5%)	1.00

Single isolate in one patient	15 	(19.7%)	12 	(26.7%)	0.38

Klebsiella pneumoniae	4	(4.8%)	5	(10.6%)	0.28

Streptococcus pneumoniae	1	(1.2%)	1	(2.1%)	1.00

Streptococcus species, viridans group	1	(1.2%)	0	 	1.00

Methicillin-sensitive Staphylococcus aureus	1	(1.2%)	0	 	1.00

Methicillin-resistant Staphylococcus aureus	2	(2.4%)	0	 	0.54

Pseudomonas fluorescens	1	(1.2%)	0	 	1.00

Pseudomonas putida	1	(1.2%)	0	 	1.00

Pseudomonas aeruginosa	2	(2.4%)	5	(10.6%)	0.10

Aeromonas hydrophila	1	(1.2%)	1	(2.1%)	1.00

Neisseria species	1	(1.2%)	0	 	1.00

Multiple microorganisms	2 	(2.4%)	0 	 	0.54

Methicillin-sensitive Staphylococcus aureus and Pseudomonas fluorescens	1	(1.2%)	0	 	1.00

Methicillin-resistant Staphylococcus aureus and Klebsiellapneumoniae	1	(1.2%)	0	 	1.00

	NTM lung diseases patients (N = 84)	Non-NTM BE patients (N = 47)	P value

Any isolates	17	(20.2%)	12	1.00

Multiple microorganisms	2	(2.4%)	0	0.54

Methicillin-sensitive Staphylococcus aureus and Pseudomonas fluorescens	1	(1.2%)	0	1.00

Methicillin-resistant Staphylococcus aureus and Klebsiellapneumoniae	1	(1.2%)	0	1.00


Disease condition	No (n, %)	Somewhat (n, %)	Yes (n, %)

Endocrine disorders (diabetes mellitus, thyroid disease)	81	36.7 %	65	29.4 %	75	33.9 %

Acute coronary syndrome	3	1.4 %	41	18.6 %	177	80.1 %

Hypertension	119	54.1 %	60	27.3 %	41	18.6 %

Thromboembolic disease (DVT and PE)	65	29.4 %	53	24.0 %	103	46.6 %

Asthma/COPD	192	86.9 %	18	8.1 %	11	5.0 %

Trauma	76	34.5 %	61	27.7 %	83	37.7 %

Partner abuse	6	2.7 %	48	21.7 %	167	75.6 %

Carotid/vertebral artery dissections	162	73.6 %	35	15.9 %	23	10.5 %

Neurologic conditions (multiple sclerosis, myasthenia gravis, CVA, seizures, headache)	67	30.3 %	60	27.1 %	94	42.5 %

GI conditions (biliary disease, dyspepsia, IBS, appendicitis, abdominal pain)	55	24.9 %	64	29.0 %	102	46.2 %

Substance abuse	121	55.0 %	63	28.6 %	36	16.4 %

Depression/suicide	39	17.8 %	51	23.3 %	129	58.9 %

Urinary tract disorders	18	8.1 %	45	20.4 %	158	71.5 %

Sexually transmitted diseases	25	11.3 %	49	22.2 %	147	66.5 %

HIV/AIDS	144	65.5 %	46	20.9 %	30	13.6 %

Autoimmune disease	27	12.3 %	67	30.5 %	126	57.3 %

Pulmonary disease (sarcoidosis, PPH)	129	58.4 %	53	24.0 %	39	17.6 %

Osteoporosis/fracture management	41	18.6 %	44	19.9 %	136	61.5 %

Pain management	150	68.2 %	44	20.0 %	26	11.8 %

Pharmacokinetics	135	61.4 %	63	28.6 %	22	10.0 %

Communication styles	60	27.1 %	81	36.7 %	80	36.2 %

Disease condition	No (n, %)	Somewhat (n, %)	Yes (n, %)

Endocrine disorders (diabetes mellitus, thyroid disease)	81	36.7 %	65	29.4 %	75

Acute coronary syndrome	3	1.4 %	41	18.6 %	177

Hypertension	119	54.1 %	60	27.3 %	41

Thromboembolic disease (DVT and PE)	65	29.4 %	53	24.0 %	103

Asthma/COPD	192	86.9 %	18	8.1 %	11

Trauma	76	34.5 %	61	27.7 %	83

Partner abuse	6	2.7 %	48	21.7 %	167

Carotid/vertebral artery dissections	162	73.6 %	35	15.9 %	23

Neurologic conditions (multiple sclerosis, myasthenia gravis, CVA, seizures, headache)	67	30.3 %	60	27.1 %	94

GI conditions (biliary disease, dyspepsia, IBS, appendicitis, abdominal pain)	55	24.9 %	64	29.0 %	102

Substance abuse	121	55.0 %	63	28.6 %	36

Depression/suicide	39	17.8 %	51	23.3 %	129

Urinary tract disorders	18	8.1 %	45	20.4 %	158

Sexually transmitted diseases	25	11.3 %	49	22.2 %	147

HIV/AIDS	144	65.5 %	46	20.9 %	30

Autoimmune disease	27	12.3 %	67	30.5 %	126

Pulmonary disease (sarcoidosis, PPH)	129	58.4 %	53	24.0 %	39

Osteoporosis/fracture management	41	18.6 %	44	19.9 %	136

Pain management	150	68.2 %	44	20.0 %	26

Pharmacokinetics	135	61.4 %	63	28.6 %	22

Communication styles	60	27.1 %	81	36.7 %	80


	Explicit LearningGroup (n = 40)	Implicit Learning Group (n = 40)	ControlGroup (n = 40)

T1Intervention	30 side-step cutting trials -Detailed verbal instructions on performance will be given	30 side-step cutting trials - Best performance will be shown	30 side-step cutting trials -No feedback on performance will be given

T2Retention test (one week post intervention)	30 side-step cutting trials -No feedback on performance will be given	30 side-step cutting trials -No feedback on performance will be given	30 side-step cutting trials -No feedback on performance will be given

T3Retention test (one month post intervention)	30 side-step cutting trials -No feedback on performance will be given	30 side-step cutting trials -No feedback on performance will be given	30 side-step cutting trials -No feedback on performance will be given


Population/Gender (N)	G6PD variant allele frequency

	Mahidol	Viangchan	Chinese 4	Union	Canton	Kaiping	Gaohe

Thai

Male (84)	0.04	0.01	-	0.01	0.02	0.012	-

Female (233)	0.01	0.006	0.006	0.002	-	0.002	0.002

Burmese

Male (11)	0.18	-	-	-	-	-	-

Female (172)	0.07	-	-	-	-	0.003	-

Population/Gender (N)	G6PD variant allele frequency

	Mahidol	Viangchan	Chinese 4	Union	Canton	Kaiping	Gaohe

Burmese

Male (11)	0.18	-	-	-	-	-	-

Female (172)	0.07	-	-	-	-	0.003	-


Models	BM	GM-A	GM-B	LRM-1	LRM-2

LRM-2	.	.	.	.	100 % (46)


Demographic information	Patients

Sex Ratio	12 women and 7 men

Age (years)	56 ± 8.96

Height (cm)	164.52 ± 5.09

Weight (kg)	76.52 ± 12.87

BMI (Kg/m2)	28.33 ± 4.65

Diabetic History (years)	11.84 ± 6.93


Axillary vs. tympanic temperature	Correlation Coefficient	Bias ± SD	95% CI	Limits of agreement

 	0.697	−0.093 ± 0.72	−0.20; 0.02	−1.54 to 1.36


	Overall cohort	PS-matched cohort

	Group A	Group B	Difference Group B – Group A	p	Group A	Group B	Difference Group B – Group A	p

n. GP Visits mean (±SE)	0.84 (±0.09)	0.38 (±0.12)	-0.46	<0.001	0.85 (±0.15)	0.38 (±0.12)	-0.47	<0.001


verity of pre-eclampsia	ild

	Severe	3.85	1.69 - 8.80	0.001


Isolate	Geographic origin	Year	Sourcea	Alternative ID	GenBank/ EBI accession number

Rs 10	New Brunswick, Canada	2009	Salmo salar (sw)	 	ERR327945

Rs 2	New Brunswick, Canada	2005	S. salar (sw)	 	ERR327951

Rs 3	New Brunswick, Canada	2005	S. salar (fw)	 	ERR327947

Rs 4	New Brunswick, Canada	2006	S. salar (sw)	 	ERR327946

Rs 5	New Brunswick, Canada	2007	S. salar (sw)	 	ERR327950

Rs 6	New Brunswick, Canada	2007	S. salar (sw)	 	ERR327953

Rs 8	New Brunswick, Canada	2008	S. salar (sw)	 	ERR327944

BPS 91	Nanaimo, BC, Canada	1991	Oncorhynchus gorbuscha	 	ERR327952

BQ96 91-1	Nanaimo, BC, Canada	1996	Oncorhynchus kisutch	 	ERR327963

DR143	Alberta, Canada	1972	Salvelinus fontinalis (fw)b	 	ERR327954

5006	Bella Bella, BC, Canada	1996	O. kisutch (sw)	960046	ERR327942

5223	Kvinnherad, Hordaland, Norway	2005	S. salar (sw)	2005-50-579	ERR327964

6553	Hemne, Sør-Trøndelag, Norway	2008	S. salar (sw)	2008-09-495	ERR327955

6642	Hemne, Sør-Trøndelag, Norway	2008	S. salar	2008-06-633	ERR327956

6694	Hemne, Sør-Trøndelag, Norway	2008	Oncorhynchus mykiss (sw)	 	ERR327962

6695	Hemne, Sør-Trøndelag, Norway	2008	O. mykiss (sw)	2008-06-631	ERR327968

6863	Osterøy, Hordaland, Norway	2009	O. mykiss (sw)	 	ERR327965

7439	Sognefjorden, Sogn og Fjordane, Norway	1984	S. salar	1984-40.992	ERR327971

7441	Storfjord, Møre og Romsdal, Norway	1985	S. salar	1985-09-667	ERR327966

7448	Stranda, Møre og Romsdal, Norway	1986	S. salar	1986-09-4366	ERR327970

7449	Skjervøy, Troms, Norway	1987	S. salar	1987-09-932	ERR327969

7450	Askøy, Hordaland, Norway	1987	S. salar	1987-09-1185	ERR327967

684	Aurland, Sognefjorden, Norway	1987	S. trutta (fw)	 	ERR327958

1205	UK	2001	O. mykiss	3104-67	ERR327930

5007	Scotland	2005	O. mykiss	0180-18	ERR327923

7105	UK	2007	O. mykiss (fw)	P0416 T83 10-3 2	ERR327932

9025	Yorkshire, England, UK	2009	O. mykiss (fw)	16251-1	ERR327912

96071	England, Hampshire, site Z, UK	1996	O. mykiss (fw)	 	ERR327927

99326	Wales, site Y, UK	1999	O. mykiss (fw)	2119-8	ERR327938

99327	UK	1997	O. mykiss (fw)	970313-2	ERR327931

99329	Wales, site X, UK	1998	O. mykiss (fw)	980036-125	ERR327937

99332	Wales, site Y, UK	1999	O. mykiss (fw)	2119-3	ERR327943

99333	Wales, site X, UK	1998	O. mykiss (fw)	980036-102	ERR327921

99341	Hampshire, site Z, England, UK	1998	O. mykiss (fw)	980109-20	ERR327949

99344	Hampshire, England, UK	1998	O. mykiss (fw)	980106-1.1.5	ERR327940

99345	Wales, site X	1998	O. mykiss (fw)	980070-18	ERR327948

NCIMB 1114	River Dee, Scotland, UK	1962	S. salar (fw)b	5005	ERR327908

NCIMB 1116	River Dee, Scotland, UK	1962	S. salar (fw)b	96056	ERR327907

MT239	Scotland, UK	1988	S. salar	 	ERR327913

MT1363	Strathclyde, Scotland, UK	1993	O. mykiss (sw)	 	ERR327920

MT3277	Dumfries and Galloway Site A, Scotland,UK	2008	O. mykiss (fw)	 	ERR327926

MT3313	Central, Scotland, UK	2008	O. mykiss (fw)	 	ERR327925

MT3315	Strathclyde Site B, Scotland, UK	2008	O. mykiss (fw)	 	ERR327928

MT1262	Highlands, Scotland, UK	1992	S. salar (fw)	 	ERR327922

MT1351	Highlands, Scotland, UK	1993	S. salar (sw)	 	ERR327904

MT1470	Tayside, Scotland, UK	1994	O. mykiss (fw)	 	ERR327910

MT1511	Strathclyde Site B, Scotland, UK	1994	O. mykiss (fw)	 	ERR327914

MT1880	Strathclyde, Scotland, UK	1996	S. salar (sw)	 	ERR327909

MT2622	Strathclyde, Scotland, UK	2002	O. mykiss (sw)	 	ERR327929

MT2943	Highlands, Scotland, UK	2005	S. salar (sw)	 	ERR327936

MT2979	Highlands, Scotland, UK	2005	O. mykiss (fw)	 	ERR327935

MT3106	Strathclyde, Scotland, UK	2006	O. mykiss (fw)	 	ERR327939

MT3479	Orkney, Scotland, UK	2008	S. salar (sw)	 	ERR327933

MT3482	Strathclyde, Scotland, UK	2009	S. salar (sw)	 	ERR327934

MT3483	Strathclyde, Scotland, UK	2009	S. salar (sw)	 	ERR327941

MT444	Western Isles, Scotland, UK	1988	S. salar (sw)	 	ERR327916

MT452	Dumfries and Galloway Site A, Scotland,UK	1988	O. mykiss (fw)	 	ERR327918

MT839	Highlands, Scotland, UK	1990	S. salar (sw)	 	ERR327917

MT861	Scotland	1990	S. salar (sw)	 	ERR327919

Car 96	Washington State, USA	1996	O. tshawytscha	 	ERR327957

D6	Oregon, USA	1982	O. tshawytscha	 	ERR327961

GR5	Montana, USA	1997	T. thymallus (fw)b	980036-87	ERR327959

WR99 c2	Washington State, USA	1999	O. kisutch	 	ERR327960

NCIMB 2235	Oregon, USA	1974	O. tshawytscha (sw)	ATCC33209	ERR327911

05372K	Grande Ronde Basin, Oregon, USA	2005	O. tshawytscha (sw)	 	ERR327906

Carson 5b	Confluence Tyee Creek & Wind River, WA, USA	1994	O. tshawytscha (fw)	 	ERR327905

Cow-chs-94	Cowlitz River, Washington	1994	O. tshawytscha (fw)	 	ERR327915

ATCC 33209c	Oregon, USA	1974	O. tshawytscha (sw)	 	NC_010168.1

NCIMB 1111d	—	Not known	Not known	5004	ERR327924

Isolate	Geographic origin	Year	Sourcea

Rs 10	New Brunswick, Canada	2009	Salmo salar (sw)

Rs 2	New Brunswick, Canada	2005	S. salar (sw)

Rs 3	New Brunswick, Canada	2005	S. salar (fw)

Rs 4	New Brunswick, Canada	2006	S. salar (sw)

Rs 5	New Brunswick, Canada	2007	S. salar (sw)

Rs 6	New Brunswick, Canada	2007	S. salar (sw)

Rs 8	New Brunswick, Canada	2008	S. salar (sw)

BPS 91	Nanaimo, BC, Canada	1991	Oncorhynchus gorbuscha

BQ96 91-1	Nanaimo, BC, Canada	1996	Oncorhynchus kisutch

DR143	Alberta, Canada	1972	Salvelinus fontinalis (fw)b

5006	Bella Bella, BC, Canada	1996	O. kisutch (sw)

5223	Kvinnherad, Hordaland, Norway	2005	S. salar (sw)

6553	Hemne, Sør-Trøndelag, Norway	2008	S. salar (sw)

6642	Hemne, Sør-Trøndelag, Norway	2008	S. salar

6694	Hemne, Sør-Trøndelag, Norway	2008	Oncorhynchus mykiss (sw)

6695	Hemne, Sør-Trøndelag, Norway	2008	O. mykiss (sw)

6863	Osterøy, Hordaland, Norway	2009	O. mykiss (sw)

7439	Sognefjorden, Sogn og Fjordane, Norway	1984	S. salar

7441	Storfjord, Møre og Romsdal, Norway	1985	S. salar

7448	Stranda, Møre og Romsdal, Norway	1986	S. salar

7449	Skjervøy, Troms, Norway	1987	S. salar

7450	Askøy, Hordaland, Norway	1987	S. salar

684	Aurland, Sognefjorden, Norway	1987	S. trutta (fw)

1205	UK	2001	O. mykiss

5007	Scotland	2005	O. mykiss

7105	UK	2007	O. mykiss (fw)

9025	Yorkshire, England, UK	2009	O. mykiss (fw)

96071	England, Hampshire, site Z, UK	1996	O. mykiss (fw)

99326	Wales, site Y, UK	1999	O. mykiss (fw)

99327	UK	1997	O. mykiss (fw)

99329	Wales, site X, UK	1998	O. mykiss (fw)

99332	Wales, site Y, UK	1999	O. mykiss (fw)

99333	Wales, site X, UK	1998	O. mykiss (fw)

99341	Hampshire, site Z, England, UK	1998	O. mykiss (fw)

99344	Hampshire, England, UK	1998	O. mykiss (fw)

99345	Wales, site X	1998	O. mykiss (fw)

NCIMB 1114	River Dee, Scotland, UK	1962	S. salar (fw)b

NCIMB 1116	River Dee, Scotland, UK	1962	S. salar (fw)b

MT239	Scotland, UK	1988	S. salar

MT1363	Strathclyde, Scotland, UK	1993	O. mykiss (sw)

MT3277	Dumfries and Galloway Site A, Scotland,UK	2008	O. mykiss (fw)

MT3313	Central, Scotland, UK	2008	O. mykiss (fw)

MT3315	Strathclyde Site B, Scotland, UK	2008	O. mykiss (fw)

MT1262	Highlands, Scotland, UK	1992	S. salar (fw)

MT1351	Highlands, Scotland, UK	1993	S. salar (sw)

MT1470	Tayside, Scotland, UK	1994	O. mykiss (fw)

MT1511	Strathclyde Site B, Scotland, UK	1994	O. mykiss (fw)

MT1880	Strathclyde, Scotland, UK	1996	S. salar (sw)

MT2622	Strathclyde, Scotland, UK	2002	O. mykiss (sw)

MT2943	Highlands, Scotland, UK	2005	S. salar (sw)

MT2979	Highlands, Scotland, UK	2005	O. mykiss (fw)

MT3106	Strathclyde, Scotland, UK	2006	O. mykiss (fw)

MT3479	Orkney, Scotland, UK	2008	S. salar (sw)

MT3482	Strathclyde, Scotland, UK	2009	S. salar (sw)

MT3483	Strathclyde, Scotland, UK	2009	S. salar (sw)

MT444	Western Isles, Scotland, UK	1988	S. salar (sw)

MT452	Dumfries and Galloway Site A, Scotland,UK	1988	O. mykiss (fw)

MT839	Highlands, Scotland, UK	1990	S. salar (sw)

MT861	Scotland	1990	S. salar (sw)

Car 96	Washington State, USA	1996	O. tshawytscha

D6	Oregon, USA	1982	O. tshawytscha

GR5	Montana, USA	1997	T. thymallus (fw)b

WR99 c2	Washington State, USA	1999	O. kisutch

NCIMB 2235	Oregon, USA	1974	O. tshawytscha (sw)

05372K	Grande Ronde Basin, Oregon, USA	2005	O. tshawytscha (sw)

Carson 5b	Confluence Tyee Creek & Wind River, WA, USA	1994	O. tshawytscha (fw)

Cow-chs-94	Cowlitz River, Washington	1994	O. tshawytscha (fw)

ATCC 33209c	Oregon, USA	1974	O. tshawytscha (sw)

NCIMB 1111d	—	Not known	Not known